

## ECFS NEWSLETTER - Issue 60 -May 2019

- 1 - [Letter from the President](#)
- 2 - [Board Elections](#)
- 3 - [ECFS Annual General Meeting](#)
- 4 - [Liverpool highlights](#)
- 5 - [Conference App](#)
- 6 - [ECFS Award](#)
- 7 - [Gerd Döring Award](#)
- 8 - [CF Courses](#)
- 9 - [ECFS Tomorrow](#)
- 10 - [Meetings in Liverpool](#)
- 11 - [2019 Basic Science Conference](#)
- 12 - [ECFS Basic Science WG Workshop](#)
- 13 - [ECFS Education Platform](#)
- 14 - [Upcoming Events](#)
- 15 - [Current References in CF](#)

European Cystic Fibrosis Society  
 Kastanieparken 7,  
 7470 Karup, Denmark  
 Tel: +45 86 676260  
 Fax: +45 86 676290  
 Email: [info@ecfs.eu](mailto:info@ecfs.eu)  
 Website: [www.ecfs.eu](http://www.ecfs.eu)

### 01.Letter from the President

Dear Friends,

There has been a lot of activity at the ECFS since the last edition of our newsletter and here is a brief review of the special projects, what's new with our society and a few highlights of the upcoming 42<sup>nd</sup> European Cystic Fibrosis Conference taking place in a few days, this year in Liverpool, United Kingdom.



But first, let me remind you of the **ECFS elections**, which are taking place this month. There are two vacancies at the Board this year. Prof. Margarida Amaral is ending her second term and Prof. Isabelle Sermet finishes her first term and our gratitude goes to both for their contribution to the Board over these last years.

Three candidates applied for these positions as Board members: Trudy Havermans, Claus Moser and Isabelle Sermet.

Your involvement in the ECFS Board Elections is critical and will contribute to shape the future direction of the Society. It is essential that the Board has a strong and engaged membership to provide leadership to our Society. So, if you have not voted yet, please log in and vote [here](#) without delay.

The results of the elections will be announced at the Annual General Meeting (AGM) in Liverpool on Friday 07 June (18:30-19:30, Hall 1C). The AGM is open to all ECFS members and we very much hope that as many of you as possible will attend it. With the elections, the AGM is the moment where members can express their wishes and expectations for the Society. We value your involvement and hope to see more members contribute and input new ideas.

More information on the AGM will appear further down in the newsletter.

The **16<sup>th</sup> ECFS Diagnostic Network Working Group** Meeting took place in Tunis in February, hosted by Samia Hamouda, and all agreed this was a fantastic meeting scientifically and with excellent networking opportunities.

The **ECFS Basic Science Conference** was held in Croatia this year, 27-30 March 2019. Once again, the conference was a resounding success. We would like to thank the organisers, Isabelle Callebaut (FR), Carlos Farinha (PT) and Martin Mense (US) for putting together a high-quality programme. The [abstract book](#) is available on the ECFS website.

We are rapidly approaching our annual conference in Liverpool and the final preparations are well under way. The Scientific Committee has put together an outstanding programme and we have some exciting new basic research and results from clinical trials to discuss. You can find the [final programme](#) on the ECFS website. I would like to thank the Scientific Committee and the Steering Committee for all their hard work over the last year in preparing the programme, selecting the abstracts and sorting the various sessions. Besides the conference App featuring the programme and other useful information, other initiatives to note include the Interactive Case studies session, some 'meet the expert' sessions organised at lunchtime and open to all, and the ECFS Tomorrow lounge which will feature a series of interesting sessions. We will also continue the CF Innovation Zone that we launched in Belgrade last year, giving the opportunity to health start-ups and innovators to demonstrate their new solutions, applications and technologies.

As part of our commitment to support young researchers, three Young Investigators Awards and 20 travel grants have been awarded to young investigators based on the merit of their abstract submissions. Congratulations to them for their prize!

Please don't miss a visit to the "CF Community" booth area in the Exhibition Hall for information on the various initiatives and programmes. If you are looking for a position or have a job opening to advertise, please send us the information to post on the website and bring an A4 advertisement to the ECFS booth at the conference.

Many thanks, as always, to Dr. Henry Ryley for compiling the current references in Cystic Fibrosis contained at the end of this Newsletter.

Please contact us if you have news items you would like to have included in future Newsletters or published on our website.

Yours sincerely,

Isabelle Fajac  
ECFS President

## 02. ECFS Board Elections - Cast your vote!

The ECFS is holding elections for 2 ECFS Board Members Positions: Margarida Amaral completed her second term and Isabelle Sermet finishes a first tenure.

Invitations to take part in the elections have been sent to the ECFS electorate by email.

Candidates information and links to supporting documents such as the candidates' nominations, application letters and CVs are [available](#) on the ECFS website.

The election deadline is 6 June 2019, 19:30 CEST.

## 03. ECFS Annual General Meeting @ Liverpool2019

The Annual General Meeting will be held on Friday, 07 June 2019, 18:30-19:30, at the Arena and Convention Centre in Liverpool (Hall 1C).

The Annual General Meeting agenda:

1. President's Report – Isabelle Fajac
2. Secretary's Report – Isabelle Sermet
3. Treasurer's Report – Kevin Southern
4. ECFS Board Elections – Isabelle Sermet
5. Update on Journal of Cystic Fibrosis – Scott Bell
6. CTN Report – Silke van Koningsbruggen-Rietschel
7. ECFS Standards of Care Report – Carlo Castellani
8. ECFS Patient Registry Report – Lutz Nährlich
9. ECFS Education Report – Daniel Peckham
10. ECFS Working Group Reports
  - [Antimicrobial Resistance Working Group](#)
  - [Basic Science Working Group](#)
  - [Diagnostic Network Working Group](#)
  - [Exercise Working Group](#)
  - [Fungal Pathogens Working Group](#)
  - [Mental Health Working Group](#)
  - [Neonatal Screening Working Group](#)
  - [Pulmonary Exacerbations Working Group](#)
11. ECFS Special Interest Groups
  - [Nursing Special Interest Group](#)
  - [European CF Pharmacy Group](#)
  - [European CF Nutrition Group](#)
  - [European Psychosocial Special Interest Group](#)
12. Presentation of the 2020 European CF Conference
13. AOB

We hope to see you!

## 04. Liverpool Highlights

Like the Beatles used to sing...  *It won't be long, it won't be long 'till  .. we meet you in Liverpool!*  
You can find all the details about the scientific programme [here](#).

A complimentary shuttle service will be offered to a limited number of delegates attending the European Cystic Fibrosis Conference at ACC Liverpool. Delegates arriving at Liverpool John Lennon or Manchester Airport on Tuesday, June 4 and Wednesday, June 5 will be transferred to ACC Liverpool and designated conference hotels.

A return service will be provided on Saturday, June 8 and Sunday, June 9.

All journeys must be booked in advance. This complimentary service is on first come, first served basis.  
Please click [here](#) to reserve a place and find out more.

Below are some highlights of the conference.

# HIGHLIGHTS OF THE CONFERENCE



## INTERACTIVE CASE STUDIES



**FRIDAY 08:30 – 10:00 / Hall 1B**  
Live voting will be done through the Conference App.

Install the ECFS 2019 Conference App, click on the Voting Button and enter the room name. Each interactive case features an evolving patient history and a series of questions designated to test your diagnostic and/or therapeutic skills. You will receive immediate feedback on your answers and treatment choices, along with the opportunity to compare your final score with those of your peers.

### ECFS TOMORROW LOUNGE

The ECFS Tomorrow initiative is geared towards bringing together those who are interested in building their future career in the cystic fibrosis community and the ECFS of tomorrow.

### CF INNOVATION ZONE

In this new zone, you will discover start-ups and innovative companies showcasing their exciting new solutions in technology and health. Open your mind to new possibilities and feel inspired!

**THURSDAY 10:00 – 10:30**  
Meet the health tech pioneers in the ePoster Corner C.

### MEET THE EXPERT SESSIONS

**THURSDAY & FRIDAY 12:45 – 13:45**  
**ePOSTER CORNERS and Room 4B**

In these small interactive sessions, you will have the opportunity to ask questions and discuss a specific topic with experts from the field. The format encourages a more personal approach to learning. Entrance to the Meet the Experts is free of charge and is on a first come, first served basis! Attendees do not need to book in advance.



## 05. Liverpool 2019 Conference App

Nearly 70% of the delegates downloaded and used the Conference App in Belgrade last year. Via the app, you are able to view all the information on the scientific programme, the exhibitors, the abstracts and ePosters. The ECFS 2019 Conference App is designed to enhance the experience of the participants before, during and after the Conference. Further information is available on the conference website and the App will soon be ready to download.

**DOWNLOAD THE ECFS 2019  
CONFERENCE APP**

**USE YOUR SMARTPHONE OR  
TABLET TO EASILY NAVIGATE  
ECFS 2019!**

- Interactive Conference Programme
- Abstracts and ePosters available via the Library
- Maps and Floor Plans
- Vote via the App during sessions marked with 
- Keep up to date with the new functionality "My Messages"



 Search for "ECFS 2019" in Apple App Store or Google Play Store



## 06. ECFS Award 2019

The ECFS Award is given annually to honour a person who has made an outstanding contribution to our basic understanding of Cystic Fibrosis or to the treatment or care of patients with Cystic Fibrosis. This year, the ECFS wishes to acknowledge **Prof. Stuart Elborn**.

Stuart Elborn has for more than two decades been a leading international clinician and scientist in CF. He has also contributed to the ECFS as Board member and President. Stuart was trained in Belfast and helped develop CF centres for adults in Nottingham and Cardiff. When he returned to Belfast in 1995, he started a new adult CF Centre providing care for all adults with cystic fibrosis in Northern Ireland. Besides being director of the Adult CF Centre, he became Professor of Respiratory Medicine at Queen's University Belfast and later the Dean of Medicine, Dentistry and Biomedical Sciences.



He was Chairman of the Research and Medical advisory committees of the Cystic Fibrosis Trust UK (2002-14) and is now member of its scientific board. After having been elected as a member of the board of the ECFS he served as its President 2007-15, during which he further developed the ECFS to its leading role in International Cystic Fibrosis care, research and education. During his time as President, the ECFS Clinical Trials Network started, and the European Cystic Fibrosis Registry consolidated. As a recognition for Stuart's service to the health care in Northern Ireland he received the title of Commander of the Order of the British Empire in 2012. In October 2016, Stuart moved to the Royal Brompton and Imperial College in London as centre director and clinical professor of respiratory medicine. He returned to Queen's University Belfast this year to lead the Faculty of Medicine, Health and Life Sciences as Pro-Vice Chancellor and Professor of Medicine. In this role, he is leading a major development in digital health in Northern Ireland as part of a Regional City Deal.

He has made a broad contribution to CF research focused on clinically important CF-topics such as microbiology and host inflammation, anti-bacterial agents, CFTR potentiators, and anti-inflammatory agents. He has led a number of key clinical trials in these areas and is still active in this area. He has also led international guidelines which have improved the standard of care for CF patients. He has supported research in the multidisciplinary team and supervised scientists, medical doctors, physiotherapists and nurses to higher degrees in research. Many of those he has mentored are scientific and clinical leaders in CF and related lung diseases. He has also contributed to research and guideline development in bronchiectasis and leads a major European project in antibiotic treatment in bronchiectasis and CF through the Innovative Medicine Initiative programme in EC Framework 7. Stuart is a strong role model as a clinical academic combining clinical care and research aimed at improving outcomes in people with CF. He passionately champions interdisciplinary person-centred care delivery, driven by data and implemented with respect and compassion.

## 07. Gerd Döring Award

Professor Gerd Döring was an outstanding leader of the ECFS. During his Presidency the number of members doubled. During this time, he also initiated a highly successful annual conference on basic science and consensus conferences on the treatment of lung infection, early intervention and prevention of lung disease, drug inhalation and related devices, nutrition, along with recommendations for several clinical trials in Cystic Fibrosis, which have had a significant impact on treatment.

The support of young investigators was a high priority for him and to honour his enormous contribution, the ECFS has initiated a Gerd Döring Award that will be given annually to honour an exceptional early career young European scientist.

The award is primarily judged on a paper published in the previous 3 calendar years, which has made a significant impact on the understanding or treatment of Cystic Fibrosis. This year, the Gerd Döring Award has been granted to **Dr. Elvira Sondo**, in acknowledgement of her recent remarkable contribution to Cystic Fibrosis. The Award, which includes a monetary grant of 5.000 Euro to support research, will be presented during the Opening Plenary of the Liverpool Conference.

In 2005, after graduating with honors in Biological Sciences at the University Federico II of Naples, Elvira Sondo joined the UOC Genetica Medica of Istituto Giannina Gaslini in Genoa, Italy. At the time, she was actively involved in a scientific project coordinated by Prof. Luis Galietta, that led to the molecular identification of the long-sought alternative calcium-dependent Cl- channel TMEM16A, published in 2008 in Science. Moreover, the study of the structure / function relationship of the TMEM16A protein and the role of the other anoctamines belonging to the TMEM16 family was the topic of her doctoral project obtained at the University of Genoa in 2016.

More recently she was enrolled as a fellow in several projects funded by the Italian Cystic Fibrosis Foundation coordinated by Dr. Nicoletta Pedemonte aimed at the identification of novel therapeutic strategies for cystic fibrosis (CF). In particular, Elvira focused her attention on CFTR pharmacology with several publications reporting the identification of CFTR correctors and potentiators by high-throughput methods and their evaluation in native epithelial cells.

In 2018 Elvira first-authored a paper reporting the discovery of the first pharmacological modulator of the ubiquitin ligase RNF5. Indeed, previous works demonstrated that genetic suppression of RNF5 in vivo leads to an attenuation of intestinal pathological phenotypes in CF mice. Elvira used a computational approach to discover inh-02, a drug-like small molecule that inhibits RNF5 and is able to rescue F508del-CFTR processing defect in primary bronchial epithelial cells from patients with CF. This work validates RNF5 as a drug target for CF, providing evidence to support its druggability. RNF5 inhibition in patients with CF and chronic lung infection could also have secondary beneficial effects, since RNF5 regulation of autophagy is involved in the innate host defense against bacterial infection.

This year Elvira has also been the recipient of a Young Investigator Grant from the Italian Ministry of Health.

Elvira will present her research at the conference in Liverpool, in the Late Breaking Science Session scheduled on Friday, June 7, 17:00 – 18:30 in Hall 1C.

## 08.CF Courses



Education is one of the major objectives for the ECFS. Several courses will be organised prior to the conference:

- Acceptance and Commitment Therapy for Cystic Fibrosis: an introduction- Tuesday 04 June 2019 - 09:00 - 17:00
- Physiotherapy Short Course - Exercise Testing in Cystic Fibrosis - Who, When and Why? - Tuesday 04, 08:00 - 17:30 and Wednesday 05 June 2019, 08:30-12:00
- Nutrition Advanced Course – Scrutinizing the future for Nutrition in Cystic Fibrosis - Tuesday 04 June 2019 - 12:30 - 17:00
- An Introductory Course, for all team members, in Cognitive Behavioral Therapy and Interpersonal Therapy - Wednesday 05 June 2019 - 09:00 - 17:00

More information about these courses can be found [here](#)

## 09.ECFS Tomorrow



We see the ECFS Tomorrow as a means to improve one of the fundamental objectives of the Society – to support and engage young scientists working in the field of Cystic Fibrosis. It is essential to provide professionals who are new to the community with opportunities to connect in a meaningful way with current leaders and experts. In turn, the new generation of specialists bring up-to-date approaches and practices to the wealth of experience that already exists within the society's ranks.

Located adjacent to the Exhibition Area of the conference venue, the ECFS Tomorrow Lounge will feature interactive workshops organised by the ECFS Special Interest Groups on Thursday and Friday. Come and take an active part in the debate and discussions on different aspects of cystic fibrosis management and care.

### WEDNESDAY, JUNE 5

**20:00 – 21:00** Meet & Greet

### THURSDAY, JUNE 6

**12:45 – 13:45** Mental Health in my hospital: tools to start screening and how to move on  
Urszula Borawska-Kowalczyk, Warsaw, PL / Anna Georgioupolous, Boston, US / Annette Katscher-Peitz, Stuttgart, DE / Yvonne Prins, Amsterdam, NL / Marieke Verkleij, Amsterdam, NL

**14:00 – 15:00** How do we cope with new cases of MTB?  
Majda Oštir, Ljubljana, SI

**17:00 – 18:00** Working with parents of children/adolescents with CF and the child with CF  
Sue Braun, Brussels, BE / Angelique Tijtgat, Brussels, BE

### FRIDAY, JUNE 7

**12:45 – 13:45** The changing picture of nutritional management in cystic fibrosis  
Sejal Pandya, Liverpool, UK / Clare Woodland, Liverpool, UK

**14:00 – 15:00** Supporting adherence – the pharmacists' perspective  
Nicola Shaw, Leeds, UK / Siân Bentley, London, UK

### SATURDAY, JUNE 8

**10:30 – 11:00** Farewell coffee



## 10. Meetings in Liverpool

Tuesday 4 June 2019	
08:30 - 17:00	ECFS Board Meeting*
08:30 - 17:30	Physiotherapy Short Course - Exercise Testing in Cystic Fibrosis – Who, When And Why?**
09:00 – 17:00	Acceptance and Commitment Therapy for Cystic Fibrosis; an introduction**
12:30 - 17:00	Nutrition Advanced Course – Scrutinizing the future for Nutrition in Cystic Fibrosis**
Wednesday 5 June 2019	
08:30 – 12:00	Physiotherapy Short Course – Exercise Testing in Cystic Fibrosis – Who, When And Why?**
08:30 – 12:45	ECFS CTN Training and Development*
08:30 – 16:00	ECFS Nursing Special Interest Group Meeting**
09:00 – 16:30	European Cystic Fibrosis Nutrition Group Meeting**
09:00 – 17:00	An Introductory Course, for all team members, in Cognitive Behavioral Therapy and Interpersonal Therapy**
09:30 – 15:00	ECFS Neonatal Screening Working Group Meeting
09:30 – 16:45	European Psychosocial Special Interest Group (EPSIG) Meeting**
10:00 – 16:00	European Cystic Fibrosis Pharmacy Group Meeting
10:00 – 12:30	CFHealthHub: learning health system and improvement collaborative. From rescue to prevention using a digital adherence platform
11:00 – 12:30	ECFS Patient Registry Executive Committee Meeting*
12:30 – 14:00	International Physiotherapy Group for Cystic Fibrosis (IPG/CF) Annual General Meeting
12:45 – 17:30	ECFS CTN Training Research Coordinators*
13:00 – 14:30	ECFS International (Global) Cystic Fibrosis Registry Group*
13:00 – 17:00	CFHealthHub: improvement collaborative data orientation and micro systems improvement training*

**Wednesday 5 June 2019**

13:15 – 18:20	ECFS CTN Steering Committee Meeting*
14:00 – 17:00	ECFS Exercise Working Group Meeting*
14:30 – 17:00	Physiotherapy Case Presentations
14:45 – 16:00	ECFSPR Scientific Committee Meeting*
15:00 – 17:00	ECFS DNWG Sweat testing workshop
15:00 – 17:00	IJNS supplement team meeting*
16:00 – 18:00	ECFS Fungal Pathogens Working Group Meeting
16:30 – 18:30	MedDRA coding training
17:00 – 18:00	ECFS Patient Registry Software Training
17:00 – 18:30	Global CF*
17:00 – 18:30	IPG/CF Board Meeting*

**Thursday 6 June 2019**

07:00 – 08:30	Journal of Cystic Fibrosis (JCF) Editorial Board Meeting*
12:00 – 14:00	UKCFMA Meeting*
12:30 – 13:30	European Registry Data Quality Project Group Meeting*
12:30 – 14:30	ECFS CTN Standardisation Committee Meeting*
12:30 – 14:30	ECFS Standards of Care Group Meeting*
13:30 – 14:30	ECFS Patient Registry – Meeting for Interested Parties
15:30 – 17:30	CFTR2 project*
16:30 – 17:30	CF Europe Joint Project Meeting
18:00 – 19:00	ECFS Patient Registry Software Training
18:30 – 20:00	ECFS CTN Inflammatory Biomarkers Meeting
18:30 – 20:00	ECFS Education Committee Meeting*
18:30 – 20:30	ECFS Pulmonary Exacerbation Working Group Meeting*

### **Friday 7 June 2019**

07:15 – 08:15	National Institute of Health Research funding call information meeting for UK medical and allied health researchers
12:30 – 14:00	ECFS Mental Health Working Group Meeting*
12:00 – 14:00	ECFS CTN Lung Clearance Index Workshop*
12:30 – 14:30	ECFS Diagnostic Network Working Group Meeting
12:00 – 13:00	CF START Trial Investigators Meeting*
12:30 – 14:30	ECFS Patient Registry Steering Group Meeting*
15:00 – 16:00	ECFS Patient Registry Software Training
18:30 – 19:30	ECFS Annual General Meeting* – ECFS members only

### **Saturday 8 June 2019**

12:30 – 17:00	Cystic Fibrosis Trust & CF Europe Community event
13:30 – 18:00	ECFS Scientific Committee Meeting – Lyon 2020*

\* By invitation only

\*\* Extra registration needed



## 11. 2019 ECFS Basic Science Conference - Dubrovnik, Croatia



The **ECFS Basic Science Conference** was held in Dubrovnik, Croatia between 27 and 30 March 2019. With nearly 200 participants, the conference was a resounding success. We would like to thank the organisers, Isabelle Callebaut (FR), Carlos Farinha (PT) and Martin Mense (US) for putting together a high-quality programme. The [abstract book](#) is available on the ECFS website.

## 12. ECFS Basic Science WG Workshop


The ECFS Basic Science Working Group will organise its 4th workshop in Lisbon, Portugal on 22 – 26 July 2019.

Free registration - Some travel grants are available.

To apply, please send a CV, letter of motivation and recommendation letter to [ESP2019@fc.ul.pt](mailto:ESP2019@fc.ul.pt)

Application deadline: 31 May 2019

More information [here](#)



## 13. Education Platform

Each month we post a 'Highlight of the month' feature which includes relevant talks and material on a particular topic.

The topic for May 2019 is 'CF Diagnosis' and brings together symposia from the ECFS conferences in Belgrade (2018) and Seville (2017), and one presentation (both available in English and Spanish) from 'The Essential Toolkit' course.

## 14. Upcoming Events

- ECFS Board Meeting 05 June 2019, Liverpool, UK
- ECFS Annual General Assembly - 07 June 2019 – Liverpool, UK

- [42<sup>nd</sup> European CF Conference – 05-08 June 2019 –Liverpool, UK](#)
- [Summer School on epithelial systems: physiology and pathophysiology, 22-26 July 2019 – Lisbon, Portugal](#)
- [Scientific Meeting organised by Mukoviszidose e.V., 19-20 September 2019 - Schloss Montabaur,Germany](#)
- [2019 European Respiratory Society Congress 28 September – 02 October 2019 – Madrid, Spain](#)
- [North American CF Conference, 31 October – 02 November 2019, Nashville, TN, United States](#)
- [43<sup>rd</sup> European CF Conference – 03-06 June 2020, Lyon, France](#)

## 15. Current References in Cystic Fibrosis

Please go to next page.

## CF Reference List

(Complied between February -May 2019)

### Adults & Adolescents

**Burgel PR., Lemonnier L., Dehillette C., Sykes J., Stanojevic S., Stephenson AL., Paillasseur JL.**  
Cluster and CART analyses identify large subgroups of adults with cystic fibrosis at low risk of 10-year death  
*European Respiratory Journal 2019; 53: 3:1801943*

**Eschenhagen P., Schwarz C.**

Patients with cystic fibrosis become adults. Treatment hopes and disappointments  
*Internist 2019; 60: 98 - 108*

**Gunnell ET., Franceschi DK., Inscoe CR., Hartman A., Goralski JL., Ceppe A., Handly B., Sams C., Fordham LA., Lu JP., Zhou O., Lee YZ.**  
Initial clinical evaluation of stationary digital chest tomosynthesis in adult patients with cystic fibrosis  
*European Radiology 2019; 29: 1665 - 1673*

**Kazmerski TM., Miller E., Sawicki GS., Thomas P., Prushinskaya O., Nelson E., Hill K., Miller A., Emans SJ.**  
Developing Sexual and Reproductive Health Educational Resources for Young Women with Cystic Fibrosis: A Structured Approach to Stakeholder Engagement  
*Patient-Patient Centered Outcomes Research 2019; 12: 267 - 276*

**Kazmerski TM., Prushinskaya OV., Hill K., Nelson E., Leonard J., Mogren K., Pitts SAB., Roboff J., Uluer A., Emans SJ., Miller E., Sawicki GS.**  
Sexual and Reproductive Health of Young Women With Cystic Fibrosis: A Concept Mapping Study  
*Academic Pediatrics 2019; 19: 307 - 314*

**Sousa AAR., Fernandez JMB., Miller J., Mir-Montejano M.**  
Physiological study of pulmonary involvement in adults with cystic fibrosis through simulated modeling of different clinical scenarios  
*Medical & Biological Engineering & Computing 2019; 57: 413 - 425*

### Animal Model

**Bertolini A., van de Peppel IP., Doktorova-Demmin M., Bodewes FAJA., de Jonge H., Bijvelds M., Verkade HJ., Jonker JW.**  
Defective FXR-FGF15 signaling and bile acid homeostasis in cystic fibrosis mice can be restored by the laxative polyethylene glycol  
*American Journal of Physiology-Gastrointestinal and Liver Physiology 2019; 316: G404 - G411*

**Donnelley M., Morgan KS., Gradl R., Klein M., Hausermann D., Hall C., Maksimenko A., Parsons DW.**  
Live-pig-airway surface imaging and whole-pig CT at the Australian Synchrotron Imaging and Medical Beamline  
*Journal of Synchrotron Radiation 2019; 26: 175 - 183*

**Edlund A., Bargouth M., Huhn M., Abels M., Esguerra JSE., Mollet IG., Svedin E., Wendt A., Renstrom E., Zhang E., Wierup N., Scholte BJ., Flodstrom-Tullberg M., Eliasson L.**  
Defective exocytosis and processing of insulin in a cystic fibrosis mouse model  
*Journal of Endocrinology 2019; 241: 45 - 57*

**Sun XS., Yi YL., Yan ZY., Rosen BH., Liang B., Winter MC., Evans TIA., Rotti PG., Yang Y., Gray JS., Park SY., Zhou WH., Zhang YL., Moll SR., Woody L., Trani DM., Jiang LC., Vonk AM., Beekman JM., Negulescu P., Van Goor F., et al**  
In utero and postnatal VX-770 administration rescues multiorgan disease in a ferret model of cystic fibrosis  
*Science Translational Medicine 2019; 11: 485:eaau7531*

### Antimicrobials

**Ahmed MU., Velkov T., Zhou QT., Fulcher AJ., Callaghan J., Zhou FF., Chan K., Azad MAK., Li J.**  
Intracellular localization of polymyxins in human alveolar epithelial cells  
*Journal of Antimicrobial Chemotherapy 2019; 74: 48 - 57*

**Ahmed SAKS., Rudden M., Smyth TJ., Dooley JSG., Marchant R., Banat IM.**  
Natural quorum sensing inhibitors effectively downregulate gene expression of *Pseudomonas aeruginosa* virulence factors  
*Applied Microbiology and Biotechnology 2019; 103: 3521 - 3535*

**Bulitt JB., Jiao YY., Drescher SK., Oliver A., Louie A., Moya B., Tao X., Wittau M., Tsuji BT., Zavascki AP., Shin BS., Drusano GL., Sorgel F., Landersdorfer CB.**  
Four Decades of beta-Lactam Antibiotic Pharmacokinetics in Cystic Fibrosis  
*Clinical Pharmacokinetics 2019; 58: 143 - 156*

**Cafora M., Deflorian G., Forti F., Ferrari L., Binelli G., Briani F., Ghisotti D., Pistocchi A.**  
Phage therapy against *Pseudomonas aeruginosa* infections in a cystic fibrosis zebrafish model  
*Scientific Reports 2019; 9: ArNo: 1527*

**Chang RYK., Das T., Manos J., Kutter E., Morales S., Chan HK.**  
Bacteriophage PEV20 and Ciprofloxacin Combination Treatment Enhances Removal of *Pseudomonas aeruginosa* Biofilm Isolated from Cystic Fibrosis and Wound Patients  
*AAPS Journal 2019; 21: 3:UNSP 49*

**Chen QQ., Shah KN., Zhang FW., Salazar AJ., Shah PN., Li RC., Sacchettini JC., Wooley KL., Cannon CL.**  
Minocycline and Silver Dual-Loaded Polyphosphoester-Based Nanoparticles for Treatment of Resistant *Pseudomonas aeruginosa*  
*Molecular Pharmaceutics 2019; 16: 1606 - 1619*

**Cho DY., Lim DJ., Mackey C., Weeks CG., Garcia JAP., Skinner D., Zhang S., McCormick J., Woodworth BA.**  
In-vitro evaluation of a ciprofloxacin- and ivacaftor-coated sinus stent against *Pseudomonas aeruginosa* biofilms  
*International Forum of Allergy & Rhinology 2019; 9: 486 - 492*

**Clark ST., Sinha U., Zhang Y., Wang PW., Donaldson SL., Coburn B., Waters VJ., Yau YCW., Tullis DE., Guttman DS., Hwang DM.**  
Penicillin-binding protein 3 is a common adaptive target among *Pseudomonas aeruginosa* isolates from adult cystic fibrosis patients treated with beta-lactams  
*International Journal of Antimicrobial Agents 2019; 53: 620 - 628*

**Crass RL., Pai MP., Lodise TP.**  
Individualizing piperacillin/tazobactam dosing in adult patients with cystic fibrosis: can tobramycin measurements help?  
*Journal of Antimicrobial Chemotherapy 2019; 74: 126 - 129*

**Cui CY., Song SH., Yang CX., Sun XY., Huang YT., Li K., Zhao S., Zhang YL., Deng YY.**  
Disruption of Quorum Sensing and Virulence in *Burkholderia cenocepacia* by a Structural Analogue of the cis-2-Dodecenoin Acid Signal  
*Applied and Environmental Microbiology 2019; 85: 8:UNSP e00105-*

**Dolce D., Neri S., Grisotto L., Campana S., Ravenni N., Miselli F., Camera E., Zavattaro L., Braggio C., Ficarelli EV., Lucidi V., Cariani L., Girelli D., Faelli N., Colombo C., Lucanto C., Lombardo M., Magazzu G., Tosco A., et al**  
Methicillin-resistant *Staphylococcus aureus* eradication in cystic fibrosis patients: A randomized multicenter study  
*PLoS One 2019; 14: 3:e0213497*

**Fusco NM., Prescott WA., Meaney CJ.**  
Pharmacokinetic Monitoring of Vancomycin in Cystic Fibrosis Is It Time to Move Past Trough Concentrations?  
*Pediatric Infectious Disease Journal 2019; 38: 258 - 262*

**Gao YH., Hennig S., Barras M.**  
Monitoring of Tobramycin Exposure: What is the Best Estimation Method and Sampling Time for Clinical Practice?  
*Clinical Pharmacokinetics 2019; 58: 389 - 399*

- Grassi L., Batoni G., Ostyn L., Rigole P., van den Bossche S., Rinaldi AC., Maisetta G., Esin S., Coenye T., Crabbe A.**  
The Antimicrobial Peptide lin-SB056-1 and Its Dendrimeric Derivative Prevent *Pseudomonas aeruginosa* Biofilm Formation in Physiologically Relevant Models of Chronic Infections  
*Frontiers in Microbiology* 2019; 10: ArNo: 198
- Gunay N., Akar F., Gokbulut C., Sakarya S.**  
Determination of the Differences in Penetration of Tigecycline and Vancomycin Into Bronchial Epithelium of Normal and Cystic Fibrosis Lung  
*Klinik Journal* 2018; 31: 139 - 143
- Hahn A., Famous H., Jensen C., Chaney H., Sami I., Perez GF., Koumbourlis AC., Louie S., Bost JE., van den Anker JN., Freishtat RJ., Zemanick ET., Crandall KA.**  
Changes in microbiome diversity following beta-lactam antibiotic treatment are associated with therapeutic versus subtherapeutic antibiotic exposure in cystic fibrosis  
*Scientific Reports* 2019; 9: ArNo: 2534
- Hubble VB., Hubbard BA., Minrovic BM., Melander RJ., Melander C.**  
Using Small-Molecule Adjuvants to Repurpose Azithromycin for Use against *Pseudomonas aeruginosa*  
*ACS Infectious Diseases* 2019; 5: 141 - 151
- Imperi F., Ficarelli RV., Visaggio D., Leon L., Visca P.**  
Activity and Impact on Resistance Development of Two Antivirulence Fluoropyrimidine Drugs in *Pseudomonas aeruginosa*  
*Frontiers in Cellular and Infection Microbiology* 2019; 9: ArNo: 49
- Jaggupilli A., Singh N., De Jesus VC., Gounni MS., Dhanaraj P., Chelikani P.**  
Chemosensory bitter taste receptors (T2Rs) are activated by multiple antibiotics  
*FASEB Journal* 2019; 33: 501 - 517
- Koeppen K., Barnaby R., Jackson AA., Gerber SA., Hogan DA., Stanton BA.**  
Tobramycin reduces key virulence determinants in the proteome of *Pseudomonas aeruginosa* outer membrane vesicles  
*PLoS One* 2019; 14: 1:e0211290
- Kulikova VV., Chernukha MY., Morozova EA., Revtovich SV., Rodionov AN., Koval VS., Avetisyan LR., Kuliaistova DG., Shaginyan IA., Demidkina TV.**  
Antibacterial Effect of Thiosulfonates on Multiresistant Strains of Bacteria Isolated from Patients with Cystic Fibrosis  
*Acta Naturae* 2018; 10: 77 - 80
- Le Run E., Arthur M., Mainardi JL.**  
In Vitro and Intracellular Activity of Imipenem Combined with Tedizolid, Rifabutin, and Avibactam against Mycobacterium abscessus  
*Antimicrobial Agents and Chemotherapy* 2019; 63: 4:e01915-18
- Maiden MM., Zachos MP., Waters CM.**  
The ionophore oxyclozanide enhances tobramycin killing of *Pseudomonas aeruginosa* biofilms by permeabilizing cells and depolarizing the membrane potential  
*Journal of Antimicrobial Chemotherapy* 2019; 74: 894 - 906
- Massip C., Mathieu C., Gaudru C., Miaut V., Floch P., Oswald E., Segonds C., Guet-Reville H.**  
In vitro activity of seven beta-lactams including ceftolozane/tazobactam and ceftazidime/avibactam against *Burkholderia cepacia* complex, *Burkholderia gladioli* and other non-fermentative Gram-negative bacilli isolated from cystic fibrosis patients  
*Journal of Antimicrobial Chemotherapy* 2019; 74: 525 - 528
- Nichols DP., Durmowicz AG., Field A., Flume PA., VanDevanter DR., Mayer-Hamblett N.**  
Developing Inhaled Antibiotics in Cystic Fibrosis: Current Challenges and Opportunities  
*Annals of the American Thoracic Society* 2019; 16: 534 - 539
- Millar BC., Moore JE.**  
Antimycobacterial Strategies to Evade Antimicrobial Resistance in the Nontuberculous Mycobacteria  
*International Journal of Mycobacteriology* 2019; 8: 7 - 21
- Molchanova N., Wang HZ., Hansen PR., Hoiby N., Nielsen HM., Franz H.**  
Antimicrobial Activity of alpha-Peptide/beta-Peptoid Lysine-Based Peptidomimetics Against Colistin-Resistant *Pseudomonas aeruginosa* Isolated From Cystic Fibrosis Patients  
*Frontiers in Microbiology* 2019; 10: ArNo: 275
- Ract P., Dahoumane R., Gallah S., Morand P., Podglajen I., Compain F.**  
Performance evaluation of the beta LACTA (TM) Test for rapid detection of ceftazidime resistance in *Pseudomonas aeruginosa* isolates from cystic fibrosis patients  
*Journal of Microbiological Methods* 2019; 158: 21 - 24
- Roberts AEL., Powell LC., Pritchard MF., Thomas DW., Jenkins RE.**  
Anti-pseudomonad Activity of Manuka Honey and Antibiotics in a Specialized ex vivo Model Simulating Cystic Fibrosis Lung Infection  
*Frontiers in Microbiology* 2019; 10: ArNo: 869
- Rowbotham NJ., Palser SC., Smith SJ., Smyth AR.**  
Infection prevention and control in cystic fibrosis: a systematic review of interventions  
*Expert Review of Respiratory Medicine* 2019; 13: 425 - 434
- Schnapp Z., Hartman C., Livnat G., Shteinberg M., Elenberg Y.**  
Decreased Fecal Calprotectin Levels in Cystic Fibrosis Patients After Antibiotic Treatment for Respiratory Exacerbation  
*Journal of Pediatric Gastroenterology and Nutrition* 2019; 68: 282 - 284
- Stockmann C., Olson J., Rashid J., Lubsch L., Young DC., Hersh AL., Frymoyer A., Ampofo K., Liu XX., Wang YH., Sherwin CMT., Zobell JT.**  
An Evaluation of Vancomycin Area Under the Curve Estimation Methods for Children Treated for Acute Pulmonary Exacerbations of Cystic Fibrosis Due to Methicillin-Resistant *Staphylococcus aureus*  
*Journal of Clinical Pharmacology* 2019; 59: 198 - 205
- Schwarz C., Brandt C., Melichar V., Runge C., Heuer E., Sahly H., Schebek M., Koster H., Bouchara JP., Biedermann T., Meissner P., Grossé-Onnebrink J., Skopnik H., Hartl D., Sedlacek L., Tintelnot K.**  
Combined antifungal therapy is superior to monotherapy in pulmonary scedosporiosis in cystic fibrosis  
*Journal of Cystic Fibrosis* 2019; 18: 227 - 232
- Somayaji R., Parkins MD., Shah A., Martiniano SL., Tunney MM., Kahle JS., Waters VJ., Elborn JS., Bell SC., Flume PA., VanDevanter DR.**  
Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: A systematic review  
*Journal of Cystic Fibrosis* 2019; 18: 236 - 243
- Toukan Y., Gur M., Hakim F., Geffen Y., Bar-Yoseph R., Nir V., Bentur L.**  
Intermittent inhaled tobramycin and systemic cytokines response in CF patients with *Pseudomonas aeruginosa*  
*Clinical and Investigative Medicine* 2018; 41: E136 - E143
- Van Stormbroek B., Zampoli M., Morrow BM.**  
Nebulized gentamicin in combination with systemic antibiotics for eradicating early *Pseudomonas aeruginosa* infection in children with cystic fibrosis  
*Pediatric Pulmonology* 2019; 54: 393 - 398
- Yuan YP., Zai Y., Xi XP., Ma CB., Wang L., Zhou M., Shaw C., Chen TB.**  
A novel membrane-disruptive antimicrobial peptide from frog skin secretion against cystic fibrosis isolates and evaluation of anti-MRSA effect using *Galleria mellonella* model  
*Biochimica et Biophysica Acta-General Subjects* 2019; 1863: 849 - 856

## Cardiology

**Hebestreit H., Hulzebos EHJ., Schneiderman JE., Karila C., Boas SR., Kriemler S., Dwyer T., Sahlberg M., Urquhart DS., Lands LC., Ratjen F., Takken T., Varanistkaya L., Rucker V., Hebestreit A., Usemann J., Radtke T., Junge S., et al**  
Cardiopulmonary Exercise Testing Provides Additional Prognostic Information in Cystic Fibrosis  
*American Journal of Respiratory and Critical Care Medicine 2019; 199: 987 - 995*

**Schapkaitz E., Weil R., White D., Klugman S.**

Asymptomatic catheter-related venous thrombosis in a child with cystic fibrosis: When to treat?  
*Journal of Vascular Nursing 2019; 37: 43 - 45*

## Cell Biology

**Chioccioli M., Feriani L., Kotar J., Bratcher PE., Cicuta P.**  
Phenotyping ciliary dynamics and coordination in response to CFTR-modulators in Cystic Fibrosis respiratory epithelial cells  
*Nature Communications 2019; 10: ArNo: 1763*

**Dutta RK., Chinnapaiyan S., Rasmussen L., Raju SV., Unwalla HJ.**

A Neutralizing Aptamer to TGFB2 and miR-145 Antagonism Rescue Cigarette Smoke- and TGF-beta-Mediated CFTR Expression  
*Molecular Therapy 2019; 27: 442 - 455*

**Faraj J., Bodas M., Pehote G., Swanson D., Sharma A., Vij N.**  
Novel cystamine-core dendrimer-formulation rescues Delta F508-CFTR and inhibits *Pseudomonas aeruginosa* infection by augmenting autophagy  
*Expert Opinion On Drug Delivery 2019; 16: 177 - 186*

**Jennings S., Ng HP., Wang GS.**

Establishment of a Delta F508-CF promyelocytic cell line for cystic fibrosis research and drug screening  
*Journal of Cystic Fibrosis 2019; 18: 44 - 53*

**Kunzelmann K., Ousingsawat J., Cabrita I., Dousova T., Bahr A., Janda M., Schreiber R., Benedetto R.**  
TMEM16A in Cystic Fibrosis: Activating or Inhibiting?  
*Frontiers in Pharmacology 2019; 10: ArNo: 3*

**Valdivieso AG., Clauzure M., Massip-Copiz MM., Cancio CE., Asensio CJA., Mori C., Santa-Coloma TA.**  
Impairment of CFTR activity in cultured epithelial cells upregulates the expression and activity of LDH resulting in lactic acid hypersecretion  
*Cellular and Molecular Life Sciences 2019; 76: 1579 - 1593*

**Yokoyama T., Takemoto M., Hirakawa M., Saino T.**

Different immunohistochemical localization for TMEM16A and CFTR in acinar and ductal cells of rat major salivary glands and exocrine pancreas  
*Acta Histochemica 2019; 121: 50 - 55*

**Zhang SY., Wang Y., Xie W., Howe ENW., Busschaert N., Sauvat A., Leduc M., Gomes-da-Silva LC., Chen G., Martins I., Deng XX., Maiuri L., Kepp O., Soussi T., Gale PA., Zamzami N., Kroemer G.**  
Squaramide-based synthetic chloride transporters activate TFEB but block autophagic flux  
*Cell Death & Disease 2019; 10: ArNo: 242*

## CFTR

**Awatade NT., Ramalho S., Silva IAL., Felicio V., Botelho HM., de Poel E., Vonk A., Beckman JM., Farinha CM., Amaral MD.**  
R560S: A class II CFTR mutation that is not rescued by current modulators  
*Journal of Cystic Fibrosis 2019; 18: 182 - 189*

**Barnaby R., Koeppen K., Stanton BA.**

Cyclodextrins reduce the ability of *Pseudomonas aeruginosa* outer-membrane vesicles to reduce CFTR Cl<sup>-</sup> secretion  
*American Journal of Physiology-Lung Cellular and Molecular Physiology 2019; 316: L206 - L215*

**Benedetto R., Ousingsawat J., Cabrita I., Pinto M., Lerias JR., Wanitchakool P., Schreiber R., Kunzelmann K.**

Plasma membrane-localized TMEM16 proteins are indispensable for expression of CFTR  
*Journal of Molecular Medicine-jmm 2019; 97: 711 - 722*

**Bernut A., Dupont C., Ogryzko NV., Neyret A., Herrmann JL., Floto RA., Renshaw SA., Kremer L.**

CFTR Protects against Mycobacterium abscessus Infection by Fine-Tuning Host Oxidative Defenses  
*Cell Reports 2019; 26: 1828 -*

**Chen XY., Zhu SY., Zhenin M., Xu WY., Bose SJ., Wong MPF., Leung GPH., Senderowitz H., Chen JH.**

A defective flexible loop contributes to the processing and gating defects of the predominant cystic fibrosis-causing mutation  
*FASEB Journal 2019; 33: 5126 - 5142*

**Chiu WT., Tran TTV., Pan SC., Huang HK., Chen YC., Wong TW.**

Cystic Fibrosis Transmembrane Conductance Regulator: A Possible New Target for Photodynamic Therapy Enhances Wound Healing  
*Advances in Wound Care 2019; 10: ArNo: 252*

**Csanady L., Vergani P., Gadsby DC.**

Structure, gating, and regulation of the CFTR anion channel  
*Physiological Reviews 2019; 99: 707 - 738*

**Doiron JE., Le CA., Ody BK., Brace JB., Post SJ., Thacker NL., Hill HM., Breton GW., Mulder MJ., Chang SC., Bridges TM., Tang LP., Wang W., Rowe SM., Aller SG., Burlington M.**

Evaluation of 1,2,3-Triazoles as Amide Bioisosteres In Cystic Fibrosis Transmembrane Conductance Regulator Modulators VX-770 and VX-809  
*Chemistry-A European Journal 2019; 25: 3662 - 3674*

**Garcia-Mendiola T., Elosegui CG., Bravo I., Pariente F., Jacobo-Martin A., Navio C., Rodriguez I., Wannemacher R., Lorenzo E.**  
Fluorescent C-NanoDots for rapid detection of BRCA1, CFTR and MRP3 gene mutations  
*Microchimica Acta 2019; 186:*

**Gifford AH., Heltshe SL., Goss CH.**

CFTR Modulator Use Is Associated with Higher Hemoglobin Levels in Individuals with Cystic Fibrosis  
*Annals of the American Thoracic Society 2019; 16: 331 - 340*

**Gong XY., Liao Y., Ahner A., Larsen MB., Wang XH., Bertrand CA., Frizzell RA.**

Different SUMO paralogues determine the fate of wild-type and mutant CFTRs: biogenesis versus degradation  
*Molecular Biology of the Cell 2019; 30: 4 - 16*

**Kamei S., Maruta K., Fujikawa H., Nohara H., Ueno-Shuto K., Tasaki Y., Nakashima R., Kawakami T., Eto Y., Suico MA., Suzuki S., Gruenert DC., Li JD., Kai H., Shuto T.**

Integrative expression analysis identifies a novel interplay between CFTR and linc-SUMF1-2 that involves CF-associated gene dysregulation  
*Biochemical and Biophysical Research Communications 2019; 509: 521 - 528*

**Kittayaruksakul S., Sawasvirojwong S., Noitem R.,**

**Pongkorpsakol P., Muanprasat C., Chatsudthipong V.**  
Activation of constitutive androstanone receptor inhibits intestinal

CFTR-mediated chloride transport

*Biomedicine & Pharmacotherapy 2019; 111: 1249 - 1259*

**Krainer G., Treff A., Hartmann A., Stone TA., Schenkel M., Keller S., Deber CM., Schlierf M.**

A minimal helical-hairpin motif provides molecular-level insights into misfolding and pharmacological rescue of CFTR  
*Communications Biology 2018; 88: 3:UNSP 981*

**Li P., Singh J., Sun YF., Ma X., Yuan P.**

CFTR constrains the differentiation from mouse embryonic stem cells to intestine lineage cells

*Biochemical and Biophysical Research Communications 2019; 510: 322 - 328*

- Liou TG.**  
The Clinical Biology of Cystic Fibrosis Transmembrane Regulator Protein Its Role and Function in Extrapulmonary Disease  
*Chest* 2019; 155: 605 - 616
- Liu KS., Wang X., Zou C., Zhang JT., Chen H., Tsang LL., Yu MK., Chung YW., Wang JH., Dai Y., Liu Y., Zhang XH.**  
Defective CFTR promotes intestinal proliferation via inhibition of the hedgehog pathway during cystic fibrosis  
*Cancer Letters* 2019; 446: 15 - 24
- Lu BY., Li L., Schneider M., Hodges CA., Cotton CU., Burgess JD., Kelley TJ.**  
Electrochemical measurement of membrane cholesterol correlates with CFTR function and is HDAC6-dependent  
*Journal of Cystic Fibrosis* 2019; 18: 175 - 181
- Nicola T., Kabir FL., Coric T., Wall SB., Zhang WF., James M., MacEwen M., Ren CC., Halloran B., Ambalavanan N., Harris WT.**  
CFTR dysfunction increases endoglin and TGF-beta signaling in airway epithelia  
*Physiological Reports* 2019; 7: 4:e13977
- Patel W., Moore PJ., Sassano MF., Lopes-Pacheco M., Aleksandrov AA., Amaral MD., Tarran R., Gray MA.**  
Increases in cytosolic Ca<sup>2+</sup> induce dynamin- and calcineurin-dependent internalisation of CFTR  
*Cellular and Molecular Life Sciences* 2019; 76: 977 - 994
- Polgreen PM., Brown GD., Hornick DB., Ahmad F., London B., Stoltz DA., Comellas AP.**  
CFTR Heterozygotes Are at Increased Risk of Respiratory Infections: A Population-Based Study  
*Open Forum Infectious Diseases* 2018; 5: 11:UNSP ofy219
- Radosavljevic I., Stojanovic B., Spasic M., Jankovic S., Djordjevic N.**  
CFTR IVS8 Poly-T Variation Affects Severity of Acute Pancreatitis in Women  
*Journal of Gastrointestinal Surgery* 2019; 23: 975 - 981
- Sharma S., Hanukoglu I.**  
Mapping the sites of localization of epithelial sodium channel (ENaC) and CFTR in segments of the mammalian epididymis  
*Journal of Molecular Histology* 2019; 50: 141 - 154
- Swahn H., Harris A.**  
Cell-Selective Regulation of CFTR Gene Expression: Relevance to Gene Editing Therapeutics  
*Genes* 2019; 10: 3:235
- Tse CM., Yin JY., Singh V., Sarker R., Lin RX., Verkman AS., Turner JR., Donowitz M.**  
cAMP Stimulates SLC26A3 Activity in Human Colon by a CFTR-Dependent Mechanism That Does Not Require CFTR Activity  
*Cellular and Molecular Gastroenterology and Hepatology* 2019; 7: 641 - 653
- van Willigen M., Vonk AM., Yeoh HY., Kruisselbrink E., Kleizen B., van der Ent CK., Egmond MR., de Jonge HR., Braakman I., Beekman JM., van der Sluijs P.**  
Folding-function relationship of the most common cystic fibrosis-causing CFTR conductance mutants  
*Life Science Alliance* 2019; 155: 15 - 26
- Vasylieva N., Kitamura S., Dong JX., Barnych B., Hvorecny KL., Madden DR., Gee SJ., Wolan DW., Morisseau C., Hammock BD.**  
Nanobody-based binding assay for the discovery of potent inhibitors of CFTR inhibitory factor (Cif)  
*Analytica Chimica Acta* 2019; 1057: 106 - 113
- Villella VR., Venerando A., Cozza G., Esposito S., Ferrari E., Monzani R., Spinella MC., Oikonomou V., Renga G., Tosco A., Rossini F., Guido S., Silano M., Garaci E., Chao YK., Grimm C., Luciani A., Romani L., Piacentini M., et al**  
A pathogenic role for cystic fibrosis transmembrane conductance regulator in celiac disease  
*EMBO Journal* 2019; 38: 2:e100101
- Wahabi I., Fredj SH., Nefzi M., Dabboubi R., Siala H., Khalsi F., Bousetta K., Messaoud T.**  
Association of M470V polymorphism of CFTR gene with variability of clinical expression of asthma: Case-report study  
*Allergologia et Immunopathologia* 2019; 47: 159 - 165
- Yeh JT., Yu YC., Hwang TC.**  
Structural mechanisms for defective CFTR gating caused by the Q1412X mutation, a severe Class VI pathogenic mutation in cystic fibrosis  
*Journal of Physiology-London* 2019; 597: 543 - 560
- Zhong X., Chen HQ., Yang XL., Wang Q., Chen WL., Li CF.**  
CFTR activation suppresses glioblastoma cell proliferation, migration and invasion  
*Biochemical and Biophysical Research Communications* 2019; 508: 1279 - 1285
- Zhu XN., Gao L., Yan CM., He YH.**  
A novel role and mechanism of cystic fibrosis transmembrane conductance regulator in bisphenol A-induced prostate cancer  
*Journal of Cellular Biochemistry* 2019; 120: 8689 - 8695
- ## Clinical
- Abu-Zahra R., Antos NJ., Kump T., Angelopoulou MV.**  
Oral health of cystic fibrosis patients at a north American center: A pilot study  
*Medicina Oral Patologia Oral y Cirugia Bucal* 2019; 24: E379 - E384
- Blasi F., Elborn JS., Palange P.**  
Adults with cystic fibrosis and pulmonologists: new training needed to recruit future specialists  
*European Respiratory Journal* 2019; 53: 1:1802209
- Daye M., Pekcan S., Mevlitoglu I.**  
Skin Findings in Cystic Fibrosis Cases  
*Cyprus Journal of Medical Sciences* 2018; 3: 149 - 153
- Denis JA., Mazzola A., Nguyen G., Lacorte JM., Brochet C., Larsen AK., Conti F.**  
Transient increase of CA 19-9 serum concentrations in a liver transplant recipient with cystic fibrosis and hepatic abscess: a case report and brief literature review  
*Clinical Biochemistry* 2019; 64: 53 - 56
- Eckford PDW., McCormack J., Munsie L., He GM., Stanojevic S., Pereira SL., Ho K., Avolio J., Bartlett C., Yang JY., Wong AP., Wellhauser L., Huan LJ., Jiang JX., Ouyang H., Du K., Klingel M., Kyriakopoulou L., Gonska T., Moraes TJ.**  
The CF Canada-Sick Kids Program in individual CF therapy: A resource for the advancement of personalized medicine in CF  
*Journal of Cystic Fibrosis* 2019; 18: 35 - 43
- Fustik S., Jakovska T., Plaseska-Karanfilska D.**  
Hyponatremic dehydration and metabolic alkalosis as dominant manifestation in cystic fibrosis infants with mild phenotype - a case series  
*Srpski Arhiv za Celokupno Lekarstvo* 2018; 146: 581 - 583
- Guemes AGC., Lim YW., Quinn RA., Conrad DJ., Benler S., Maughan H., Edwards R., Brettin T., Cantu VA., Cuevas D., Hamidi R., Dorresteijn P., Rohwer F.**  
Cystic Fibrosis Rapid Response: Translating Multi-omics Data into Clinically Relevant Information  
*mBio* 2019; 10: 2:e00431-19
- Isaiah A., Daher A., Sharma PB., Naqvi K., Mitchell RB.**  
Predictors of sleep hypoxemia in children with cystic fibrosis  
*Pediatric Pulmonology* 2019; 54: 273 - 279
- Khosravi HM., Kermani MAH., Hassanzad M., Rezaie M., Tashayoe-Nejad S., Sayedi SJ., Velayati AA.**  
Effects of Coenzyme Q10 Level on Clinical Parameters in Cystic Fibrosis Patients  
*International Journal of Pediatrics* 2019; 7: 9285 - 9294

- Levy H., Jia S., Pan A., Zhang X., Kaldunski M., Nugent ML., Reske M., Feliciano RA., Quintero D., Renda MM., Woods KJ., Murkowski K., Johnson K., Verbsky J., Dasu T., Ideozu JE., McColley S., Quasney MW., Dahmer MK., Avner E., et al**  
Identification of molecular signatures of cystic fibrosis disease status with plasma-based functional genomics  
*Physiological Genomics* 2019; 51: 27 - 41
- Mancini V., Mastria G., Frantellizzi V., Troiani P., Zampatti S., Carboni S., Giardina E., Campopiano R., Gambardella S., Turchi F., Petolicchio B., Toscano M., Liberatore M., Vigano A., Di Piero V.**  
Migrainous Infarction in a Patient With Sporadic Hemiplegic Migraine and Cystic Fibrosis: A 99mTc-HMPAO Brain SPECT Study  
*Headache* 2019; 59: 253 - 258
- Roehmel JF., Kallinich T., Staab D., Schwarz C.**  
Clinical manifestations and risk factors of arthropathy in cystic fibrosis  
*Respiratory Medicine* 2019; 147: 66 - 71
- Sahin Y., Erkan T., Kutlu T., Kepil N., Kilinc AA., Cokugras FC., Cokugras H.**  
The Frequency of Celiac Disease in Turkish Children with Cystic Fibrosis  
*European Journal of Therapeutics* 2019; 25: 39 - 43
- Szczesniak RD., Brokamp C., Su WJ., Mcphail GL., Pestian J., Clancy JP.**  
Improving Detection of Rapid Cystic Fibrosis Disease Progression-Early Translation of a Predictive Algorithm Into a Point-of-Care Tool  
*IEEE Journal of Translational Engineering in Health and Medicine* 2019; 7: ArNo: 2800108
- Szwed A., John A., Gozdzik-Szychalska J., Czainski W., Czerniak W., Ratajczak J., Batura-Gabryel H.**  
Survival of Patients with Cystic Fibrosis Depending on Mutation Type and Nutritional Status  
*Pulmonary Disorders and Therapy* 2018; 1023: 65 - 72
- Villaverde-Hueso A., Sanchez-Diaz G., Molina-Cabrero FJ., Gallego E., de la Paz MP., Alonso-Ferreira V.**  
Mortality Due to Cystic Fibrosis over a 36-Year Period in Spain: Time Trends and Geographic Variations  
*International Journal of Environmental Research and Public Health* 2019; 16: 1:119
- ## Diabetes
- Boudreau V., Reynaud Q., Bonhoure A., Durieu I., Rabasa-Lhoret R.**  
Validation of a Stepwise Approach Using Glycated Hemoglobin Levels to Reduce the Number of Required Oral Glucose Tolerance Tests to Screen for Cystic Fibrosis-Related Diabetes in Adults  
*Canadian Journal of Diabetes* 2019; 43: 161 - 162
- Christian F., Thierman A., Shirley E., Allen K., Cross C., Jones K.**  
Sustained Glycemic Control With Ivacaftor in Cystic Fibrosis-Related Diabetes  
*Journal of Investigative Medicine High Impact Case Reports* 2019; 7: ArNo: UNSP 232
- Frost F., Nazareth D., Shaw M., Walshaw MJ.**  
Cystic fibrosis related diabetes is not independently associated with increased Stenotrophomonas maltophilia infection: Longitudinal data from updates the UK CF Registry  
*Journal of Cystic Fibrosis* 2019; 18: 294 - 298
- Geyer MC., Sullivan T., Tai A., Morton JM., Edwards S., Martin AJ., Perano SJ., Gagliardi L., Rayner CK., Horowitz M., Couper JJ.**  
Exenatide corrects postprandial hyperglycaemia in young people with cystic fibrosis and impaired glucose tolerance: A randomized crossover trial  
*Diabetes Obesity & Metabolism* 2019; 21: 700 - 704
- Gilmour JA.**  
Response to the Letter to the Editor From Dr. Boudreau et al, Validation of a Stepwise Approach Using Glycated Hemoglobin Levels to Reduce the Number of Required Oral Glucose Tolerance Tests to Screen for Cystic Fibrosis-Related Diabetes in Adults"  
*Canadian Journal of Diabetes* 2019; 43: 163
- Gilmour JA., Sykes J., Etchells E., Tullis E.**  
Cystic Fibrosis-Related Diabetes Screening in Adults: A Gap Analysis and Evaluation of Accuracy of Glycated Hemoglobin Levels  
*Canadian Journal of Diabetes* 2019; 43: 13 - 18
- Patro S., Panda SS., Mishra D., Keerthi S.**  
Burkholderia Infections in Diabetic Patients Emerging as a Challenge for Physicians: A Case Series  
*Journal of Clinical and Diagnostic Research* 2019; 13: OD04 - OD07
- Prinz N., Zolin A., Konrad K., Nahrlich L., Laubner K., Olesen HV., Bauer M., Jung A., Frischer T., Holl RW.**  
Characteristics of cystic fibrosis-related diabetes: Data from two different sources the European cystic fibrosis society patient registry and German/Austrian diabetes prospective follow-up registry  
*Pediatric Diabetes* 2019; 20: 255 - 262
- Winhofer Y., Wolf P., Felinger P., Tura A., Hillebrand P., Stauffer K., Trauner M., Jakob P., Murakoz G., Kautzky-Willer A., Pacini G., Krebs M., Luger A., Kazemi-Shirazi L.**  
Markedly delayed insulin secretion and a high rate of undetected overt diabetes characterize glucose metabolism in adult patients with cystic fibrosis after lung transplantation  
*Endocrine Practice* 2019; 25: 254 - 262
- ## Diagnosis
- Desai S., Wong H., Sykes J., Stephenson AL., Singer J., Quon BS.**  
Reply: Predictors of Reduced Survival for Adult-diagnosed Cystic Fibrosis: Older Age at Diagnosis, a Substitute for Older Age?  
*Annals of the American Thoracic Society* 2019; 16: 644 - 645
- Fieuws S., Hatzagiorgou E., De Boeck K.**  
Predictors of Reduced Survival for Adult-diagnosed Cystic Fibrosis: Older Age at Diagnosis, a Substitute for Older Age?  
*Annals of the American Thoracic Society* 2019; 16: 644
- Gramegna A., Alberti S., Seia M., Porcaro L., Bianchi V., Castellani C., Melotti P., Sorio C., Consalvo E., Franceschi E., Amati F., Contarini M., Gaffuri M., Roncoroni L., Vigone B., Bellofiore A., Del Monaco C., Oriano M., et al**  
When and how ruling out cystic fibrosis in adult patients with bronchiectasis  
*Multidisciplinary Respiratory Medicine* 2018; 13:
- Gumus E.**  
Examination of CFTR Gene Mutations in Patient Groups with Borderline Sweat Test and Clinical Preliminary Diagnosis of Cystic Fibrosis by Next-Generation Sequencing Method in Sanliurfa Province  
*Journal of Academic Research in Medicine* 2019; 9: 86 - 90
- Kinyon K.**  
New Cystic Fibrosis Diagnostic Guidelines: What Does It Mean for Your Practice?  
*Journal for Nurse Practitioners* 2019; 15: 274 - 276
- LeGrys VA., Moon TC., Laux J., Accurso F., Martiniano SA.**  
A multicenter evaluation of sweat chloride concentration and variation in infants with cystic fibrosis  
*Journal of Cystic Fibrosis* 2019; 18: 190 - 193
- Rueegg CS., Kuehni CE., Gallati S., Jurca M., Jung A., Casaulta C., Barben J., Barazzzone C., Barben J., Baumgartner M., Eng P., Fingerhut R., Hafner G., Hammer J., Mornand A., Moeller A., Mueller D., Regamey N., Rochat I., et al**  
Comparison of two sweat test systems for the diagnosis of cystic fibrosis in newborns  
*Pediatric Pulmonology* 2019; 54: 264 - 272

**Solomon GM., Bronsveld I., Hayes K., Wilschanski M., Melotti P., Rowe SM., Sermet-Gaudelus I.**  
Standardized Measurement of Nasal Membrane Transepithelial Potential Difference (NPD)  
*Journal of Visualized Experiments 2018; : 139:e57006*

## Epidemiology

**Hinds DM., Sanders DB., Slaven JE., Romero M., Davis SD., Stevens JC.**  
Cystic fibrosis in El Salvador  
*Pediatric Pulmonology 2019; 54: 369 - 371*

**Okur DS., Yuruyen C., Gungor O., Aktas Z., Erturan Z., Akcakaya N., Camcioglu Y., Cokugras H., Koksalan K.**  
Genotypic characterization of *Pseudomonas aeruginosa* isolates from Turkish children with cystic fibrosis  
*Infection and Drug Resistance 2019; 12: 675 - 685*

**Reisi M., Behnam M., Sayedi SJ., Salimi F., Kargar P., Salehi M., Saneian H., Kashani I., Kelishadi R.**  
Prevalence of Cystic Fibrosis Trans-membrane Conductance Regulator Gene common mutations in children with cystic fibrosis in Isfahan, Iran  
*International Journal of Pediatrics 2019; 7: 9333 - 9339*

## Exercise

**Causer AJ., Shute JK., Cummings MH., Shepherd AI., Bright V., Connell G., Allenby MI., Carroll MP., Daniels T., Saynor ZL.**  
Supramax exercise testing in cystic fibrosis: not ready for prime time Reply  
*Journal of Applied Physiology 2019; 126: 265*

**Cooper DM.**  
Supramax exercise testing in cystic fibrosis: not ready for prime time  
*Journal of Applied Physiology 2019; 126: 264*

**Cox NS., Pepin V., Holland AE.**  
Greater Sleep Fragmentation Is Associated With Less Physical Activity in Adults With Cystic Fibrosis  
*Journal of Cardiopulmonary Rehabilitation and Prevention 2019; 39: E11 - E14*

**Parazzi PLF., Marson FAL., Ribeiro MAGO., Schivinski CIS., Ribeiro JD.**  
Evaluation of respiratory dynamics by volumetric capnography during submaximal exercise protocol o six minutes on treadmill in cystic fibrosis patients  
*Jornal de Pediatria 2019; 95: 76 - 86*

**Tucker MA., Lee N., Rodriguez-Miguelez P., Looney J., Crandall RH., Forseen C., McKie KT., Harris RA.**  
Exercise testing in patients with cystic fibrosis: importance of ventilatory parameters  
*European Journal of Applied Physiology 2019; 119: 227 - 234*

**Ward N., Stiller K., Holland AE.**  
Exercise as a therapeutic intervention for people with cystic fibrosis  
*Expert Review of Respiratory Medicine 2019; 13: 449 - 458*

**Williams CA., Wedgwood KCA., Mohammadi H., Prouse K., Tomlinson OW., Tsaneva-Atanasova K.**  
Cardiopulmonary responses to maximal aerobic exercise in patients with cystic fibrosis  
*PLoS One 2019; 14: 2:e0211219*

**Wu K., Mathur S.**  
Clinical Usefulness of Functional Tests of Leg Muscle Strength and Power in Adults With Cystic Fibrosis  
*Respiratory Care 2019; 64: 240 - 241*

## Gastroenterology

**Henker R., Oltmanns A., Wald A., Tuennemann J., Opitz S., Hoffmeister A., Wirtz H., Mossner J., Jansen-Winkel B., Karlas T.**  
Severe ileocecal inflammatory syndrome in adult patients with cystic fibrosis  
*Zeitschrift Fur Gastroenterologie 2019; 57: 312 - 316*

**Johnson CD., Williamson N., Janssen-van Solingen G., Arbuckle R., Johnson C., Simpson S., Staab D., Dominguez-Munoz E., Levy P., Connett G., Lerch MM.**  
Psychometric evaluation of a patient-reported outcome measure in pancreatic exocrine insufficiency (PEI)  
*Pancreatology 2019; 19: 182 - 190*

## General Review

**[Anonymous].**  
The Proceedings of the 16th Italian Convention of Investigators in Cystic Fibrosis: Verona, Italy. 22-24 November 2018  
*Multidisciplinary Respiratory Medicine 2019; 14:*

**Bono-Neri F., Romano C., Isedeh A.**  
Cystic Fibrosis: Advancing Along the Continuum  
*Journal of Pediatric Health Care 2019; 33: 242 - 254*

**Goetz D., Ren CL.**  
Review of Cystic Fibrosis  
*Pediatric Annals 2019; 48: E154 - E161*

## Gene Therapy

**Guan S., Munder A., Hedtfeld S., Braubach P., Glage S., Zhang LG., Lienenklau S., Schultze A., Hasenpusch G., Garrels W., Stanke F., Miskey C., Johler SM., Kumar Y., Tummler B., Rudolph C., Ivics Z., Rosenacker J.**  
Self-assembled peptide-poloxamine nanoparticles enable in vitro and in vivo genome restoration for cystic fibrosis  
*Nature Nanotechnology 2019; 14: 287*

**Loza LIM., Yuen EC., McCray PB.**  
Lentiviral Vectors for the Treatment and Prevention of Cystic Fibrosis Lung Disease  
*Genes 2019; 10: 3:218*

**Qaisar F., Habib A., Riaz M., Rehman ZU.**  
Barriers and recent advances in non-viral vectors targeting the lungs for cystic fibrosis gene therapy  
*Nanomedicine Journal 2019; 6: 75 - 84*

**Xia E., Zhang YQ., Cao HB., Li J., Duan RQ., Hu J.**  
TALEN-Mediated Gene Targeting for Cystic Fibrosis-Gene Therapy  
*Genes 2019; 10: 1:39*

## Genetics

**Chheda P., Dama T., Goradia D., Pande S., Vinarkar S.**  
A novel CFTR gene variant - p.Tyr517\*associated with cystic fibrosis: a case report  
*Fetal and Pediatric Pathology 2018; 37: 448 - 451*

**Darrah RJ., Jacono FJ., Joshi N., Mitchell AL., Sattar A., Campanaro CK., Litman P., Frey J., Nethery DE., Barbato ES., Hodges CA., Corvol H., Cutting GR., Knowles MR., Strug LJ., Drumm ML.**  
AGTR2 absence or antagonism prevents cystic fibrosis pulmonary manifestations  
*Journal of Cystic Fibrosis 2019; 18: 127 - 134*

**Gong JF., Wang F., Xiao BW., Panjwani N., Lin F., Keenan K., Avolio J., Esmacili M., Zhang L., He GM., Soave D., Mastromatteo S., Baskurt Z., Kim S., O'Neal WK., Polineni D., Blackman SM., Corvol H., Cutting GR., Drumm M., et al**  
Genetic association and transcriptome integration identify contributing genes and tissues at cystic fibrosis modifier loci  
*PloS Genetics 2019; 15: 2:e1008007*

**Keenan K., Dupuis A., Griffin K., Castellani C., Tullis E., Gonska T.**  
Phenotypic spectrum of patients with cystic fibrosis and cystic fibrosis-related disease carrying p.Arg117His  
*Journal of Cystic Fibrosis 2019; 18: 265 - 270*

## Kurbel S.

Was the Last Ice Age dusty climate instrumental in spreading of the three "Celtic" diseases (hemochromatosis, cystic fibrosis and palmar fibromatosis)?

*Medical Hypotheses 2019; 122: 134 - 138*

## Pereira SVN., Ribeiro JD., Ribeiro AF., Bertuzzo CS., Marson FAL.

Novel, rare and common pathogenic variants in the CFTR gene screened by high-throughput sequencing technology and predicted by in silico tools

*Scientific Reports 2019; 9: ArNo: 6234*

## Petrova NV., Kashirskaya NY., Saydaeva DK., Polyakov AV., Adyan TA., Simonova OI., Gorinova YV., Kondratyeva EI., Sherman VD., Novoselova OG., Vasilyeva TA., Marakhonov AV., Macek M., Ginter EK., Zinchenko RA.

Spectrum of CFTR mutations in Chechen cystic fibrosis patients: high frequency of c.1545\_1546delTA (p.Tyr515X; 1677delTA) and c.274G > A (p.Glu92Lys; E92K) mutations in North Caucasus  
*BMC Medical Genetics 2019; 20: ArNo: 44*

## Petrova NV., Marakhonov AV., Vasilyeva TA., Kashirskaya NY., Ginter EK., Kutsev SI., Zinchenko RA.

Comprehensive genotyping reveals novel CFTR variants in cystic fibrosis patients from the Russian Federation  
*Clinical Genetics 2019; 95: 444 - 447*

## Ruiz-Cabezas JC., Barros F., Sobrino B., Garcia G., Burgos R., Farhat C., Castro A., Munoz L., Zambrano AK., Martinez M., Montalvan M., Paz-y-Mino C.

Mutational analysis of CFTR in the Ecuadorian population using next-generation sequencing  
*Gene 2019; 696: 28 - 32*

## Schucht S., Minso R., Lex C., Reiss J., Stanke F., Tamm S., van Barneveld A., Tummller B.

Functional analysis of the p.[Arg74Trp;Val201Met;Asp1270Asn]/p.Phe508del CFTR mutation genotype in human native colon  
*Molecular Genetics & Genomic Medicine 2019; 7: 2:UNSP e526*

## Szymczak A., Ksiazek P., Mojsym-Korybska S., Skorupa W., Zbikowska-Machul A.

Developing a diagnostic test to identify the selected mutation within the CFTR gene that determines the onset of cystic fibrosis  
*Current Issues in Pharmacy and Medical Sciences 2018; 31: 200 - 203*

## Wakabayashi-Nakao K., Yu YC., Nakakuki M., Hwang TC., Ishiguro H., Sohma Y.

Characterization of (G970-T1122)-CFTR, the most frequent CFTR mutant identified in Japanese cystic fibrosis patients  
*Journal of Physiological Sciences 2019; 69: 103 - 112*

## Growth & Development

### Gruet M., Saynor Z.

Assessment of Peripheral Muscle Function in Cystic Fibrosis: Why and How?

*Respiratory Care 2019; 64: 238 - 240*

### Robinson CA., Hofer M., Benden C., Schmid C.

Evaluation of bone disease in patients with cystic fibrosis and end-stage lung disease  
*Jornal Brasileiro de Pneumologia 2019; 45: 1:UNSP e201702*

## Immunology & Inflammation

### Balakrishnan A., Karki R., Berwin B., Yamamoto M., Kanneganti TD.

Guanylate binding proteins facilitate caspase-11-dependent pyroptosis in response to type 3 secretion system-negative *Pseudomonas aeruginosa*

*Cell Death Discovery 2018; 24: 5164 - 5174*

### Bezzerri V., Piacenza F., Caporelli N., Malavolta M., Provinciali M., Cipolli M.

Is cellular senescence involved in cystic fibrosis?

*Respiratory Research 2019; 20: ArNo: 32*

## Chaudhary N., Ueno-Shuto K., Ono T., Ohira Y., Watanabe K., Nasu A., Fujikawa H., Nakashima R., Takahashi N., Suico MA., Kai H., Shuto T.

Curcumin Down-Regulates Toll-Like Receptor-2 Gene Expression and Function in Human Cystic Fibrosis Bronchial Epithelial Cells  
*Biological & Pharmaceutical Bulletin 2019; 42: 489 - 495*

## Dodamani MH., Muthu V., Thakur R., Pal A., Sehgal IS., Dhooria S., Aggarwal AN., Garg M., Chakrabarti A., Agarwal R.

A randomised trial of vitamin D in acute-stage allergic bronchopulmonary aspergillosis complicating asthma  
*Mycoses 2019; 62: 320 - 327*

## Eyübüoglu TS., Aslan AT., Gursoy TR., Onay ZR., Kocak U., Tapisiz AA.

Macrophage activation syndrome due to *Nocardia* spp in a pediatric patient with cystic fibrosis  
*Pediatric Pulmonology 2019; 54: E10 - E12*

## Forrest OA., Chopyk DM., Gernez Y., Brown MR., Conrad CK., Moss RB., Tangpricha V., Peng LM., Tirouvanziam R.

Resistin is elevated in cystic fibrosis sputum and correlates negatively with lung function  
*Journal of Cystic Fibrosis 2019; 18: 64 - 70*

## Jiang KY., Poppenberg KE., Wong LP., Chen YM., Borowitz D., Goetz D., Sheehan D., Frederick C., Tutino VM., Meng H., Jarvis JN.

RNA sequencing data from neutrophils of patients with cystic fibrosis reveals potential for developing biomarkers for pulmonary exacerbations  
*Journal of Cystic Fibrosis 2019; 18: 194 - 202*

## Liou TG., Adler FR., Argel N., Asfour F., Brown PS., Chatfield BA., Daines CL., Durham D., Francis JA., Glover B., Heynekamp T., Hoidal JR., Jensen JL., Keogh R., Kopecky CM., Lechtzin N., Li YP., Lysinger J., Molina O., et al

Prospective multicenter randomized patient recruitment and sample collection to enable future measurements of sputum biomarkers of inflammation in an observational study of cystic fibrosis  
*BMC Medical Research Methodology 2019; 19: ArNo: 88*

## Margaroli C., Garratt LW., Horati F., Dittrich AS., Rosenow T., Montgomery ST., Frey DL., Brown MR., Schultz C., Guglani L., Kicic A., Peng L., Scholte BJ., Mall MA., Janssens NM., Stick SM., Tirouvanziam R.

Elastase Exocytosis by Airway Neutrophils Is Associated with Early Lung Damage in Children with Cystic Fibrosis  
*American Journal of Respiratory and Critical Care Medicine 2019; 199: 873 - 881*

## Mauch RM., Rossi CL., da Silva MTN., Aiello TB., Ribeiro JD., Ribeiro AF., Hoiby N., Levy CE.

Secretory IgA-mediated immune response in saliva and early detection of *Pseudomonas aeruginosa* in the lower airways of pediatric cystic fibrosis patients  
*Medical Microbiology and Immunology 2019; 208: 205 - 213*

## Momtazi G., Lambrecht BN., Naranjo JR., Schock BC.

Regulators of A20 (TNFAIP3): new drug-able targets in inflammation  
*American Journal of Physiology-Lung Cellular and Molecular Physiology 2019; 316: L456 - L469*

## Mulcahy EM., Cooley MA., McGuire H., Asad S., de St Groth BF., Beggs SA., Roddam LF.

Widespread alterations in the peripheral blood innate immune cell profile in cystic fibrosis reflect lung pathology  
*Immunology and Cell Biology 2019; 97: 416 - 426*

## Muraglia KA., Chorghade RS., Kim BR., Tang XX., Shah VS., Grillo AS., Daniels PN., Ciolfi AG., Karp PH., Zhu LY., Welsh MJ., Burke MD.

Small-molecule ion channels increase host defences in cystic fibrosis airway epithelia

*Nature 2019; 567: 405 - +*

## Olszowiec-Chlebna M., Koniarck-Maniecka A., Brzozowska A., Blauz A., Rychlik B., Stelmach I.

Vitamin D inhibits pro-inflammatory cytokines in the airways of cystic fibrosis patients infected by *Pseudomonas aeruginosa*- pilot study

*Italian Journal of Pediatrics 2019; 45: ArNo: 41*

## Schluchter MD., Piccorelli AV.

Shared parameter models for joint analysis of longitudinal and survival data with left truncation due to delayed entry - Applications to cystic fibrosis

*Statistical Methods in Medical Research 2019; 28: 1489 - 1507*

## Seyfarth J., Sivagurunathan S., Ricken S., Weinreich G., Olbrich L., Taube C., Mayatepek E., Schramm D., Jacobsen M.

Higher Interleukin-7 serum concentrations in patients with cystic fibrosis correlate with impaired lung function

*Journal of Cystic Fibrosis 2019; 18: 71 - 77*

## Simonin J., Bille E., Crambert G., Noel S., Dreano E., Edwards A., Hatton A., Pranke I., Villeret B., Cattart CH., Vrel JP., Urbach V., Baatallah N., Hinzpeter A., Golec A., Touqui L., Nassif X., Galietta LJ., Planelles G., et al

Airway surface liquid acidification initiates host defense abnormalities in Cystic Fibrosis

*Scientific Reports 2019; 9: ArNo: 6516*

## Villella VR., Esposito S., Ferrari E., Monzani R., Tosco A., Rossin F., Castaldo A., Silano M., Marseglia GL., Romani L., Barlev NA., Piacentini M., Raia V., Kroemer G., Maiuri L.

Autophagy suppresses the pathogenic immune response to dietary antigens in cystic fibrosis

*Cell Death & Disease 2019; 10: ArNo: 258*

## Liver Disease

### Alexopoulou A., Pouriki S., Vasilieva L., Alexopoulos T., Filaditaki V., Gioka M., Diamantea F., Dourakis SP.

Evaluation of noninvasive markers for the diagnosis of cystic fibrosis liver disease

*Scandinavian Journal of Gastroenterology 2018; 53: 1547 - 1552*

### Bader RM., Jonas MM., Mitchell PD., Wiggins S., Lee CK.

Controlled attenuation parameter: A measure of hepatic steatosis in patients with cystic fibrosis

*Journal of Cystic Fibrosis 2019; 18: 280 - 285*

### Boelle PY., Debray D., Guillot L., Clement A., Corvol H.

Cystic Fibrosis Liver Disease: Outcomes and Risk Factors in a Large Cohort of French Patients

*Hepatology 2019; 69: 1648 - 1656*

### Cortes-Santiago N., Leung DH., Castro E., Finegold M., Wu H., Patel KR.

Hepatic Steatosis Is Prevalent Following Orthotopic Liver Transplantation in Children With Cystic Fibrosis

*Journal of Pediatric Gastroenterology and Nutrition 2019; 68: 96 - 103*

### Fawcett LK., Widger J., Henry GM., Ooi CY.

Case report: Cholecystoduodenostomy for cholestatic liver disease in a premature infant with cystic fibrosis and short gut syndrome

*BMC Pediatrics 2019; 19: ArNo: 78*

### Freeman AJ., Sellers ZM., Mazariegos G., Kelly A., Saiman L., Mallory G., Ling SC., Narkevicius MR., Leung DH.

A Multidisciplinary Approach to Pretransplant and Posttransplant Management of Cystic Fibrosis-Associated Liver Disease

*Liver Transplantation 2019; 25: 640 - 657*

### Khan HH., Mew NA., Kaufman SS., Yazigi NA., Fishbein TM., Khan KM.

Unusual Cystic Fibrosis Transmembrane Conductance Regulator Mutations and Liver Disease: A Case Series and Review of the Literature

*Transplantation Proceedings 2019; 51: 790 - 793*

### Li HY., Lin L., Hu XG., Li CC., Zhang HL.

Liver Failure in a Chinese Cystic Fibrosis Child With Homozygous R553X Mutation

*Frontiers in Pediatrics 2019; 7: ArNo: 36*

### Sakiani S., Kleiner DE., Heller T., Koh C.

Hepatic Manifestations of Cystic Fibrosis

*Clinics in Liver Disease 2019; 23: 263 - +*

## Toledano MB., Mukherjee SK., Howell J., Westaby D., Khan SA., Bilton D., Simmonds NJ.

The emerging burden of liver disease in cystic fibrosis patients: A UK nationwide study

*PLoS One 2019; 14: 4:e0212779*

## Microbiology

### Ahmed B., Cox MJ., Cuthbertson L., James P., Cookson WOC., Davies JC., Moffatt MF., Bush A.

Longitudinal development of the airway microbiota in infants with cystic fibrosis

*Scientific Reports 2019; 9: ArNo: 5143*

### Ahmed MI., Kulkarni H., Shajpal S., Patel D., Patel P., Clayton A., Modha DE., Gaillard EA.

Early detection of non-tuberculous mycobacteria in children with cystic fibrosis using induced sputum at annual review

*Pediatric Pulmonology 2019; 54: 257 - 263*

### Akisoglu O., Engin D., Saricam S., Mustak HK., Sener B., Hascelik G.

Multilocus Sequence Analysis, Biofilm Production, Antibiotic Susceptibility and Synergy Tests of Burkholderia Species in Patients with and without Cystic Fibrosis

*Mikrobiyoloji Bulteni 2019; 53: 22 - 36*

### Allemann A., Kraemer JG., Korten I., Ramsey K., Casaulta C., Wuthrich D., Ramette A., Endimiani A., Latzin P., Hilti M., Barben J., Jung A., Kieninger E., Moeller A., Mornand A., Hafem G., Muller-Suter D., Regamey N., Rochat I., et al

Nasal Resistome Development in Infants With Cystic Fibrosis in the First Year of Life

*Frontiers in Microbiology 2019; 10: ArNo: 212*

### Andrew EC., Connell T., Robinson P., Curtis N., Massie J., Robertson C., Harrison J., Shanthikumar S., Bryant PA., Starr M., Steer A., Ranganathan S., Gwee A.

Pulmonary Mycobacterium abscessus complex in children with cystic fibrosis: A practical management guideline

*Journal of Paediatrics and Child Health 2019; 55: 502 - 511*

### Auster L., Sutton M., Gwin MC., Nitkin C., Bonfield TL.

Optimization of In Vitro Mycobacterium avium and Mycobacterium intracellulare Growth Assays for Therapeutic Development

*Microorganisms 2019; 7: 2:42*

### Bernardy EE., Petit RA., Moller AG., Blumenthal JA., McAdam AJ., Priebe GP., Chande AT., Rishishwar L., Jordan IK., Read TD., Goldberg JB.

Whole-Genome Sequences of *Staphylococcus aureus* Isolates from Cystic Fibrosis Lung Infections

*Microbiology Resource Announcements 2019; 8: 3:e01564-18*

### Boyle M., Moore JE., Whitehouse JL., Bilton D., Downey DG.

The diagnosis and management of respiratory tract fungal infection in cystic fibrosis: A UK survey of current practice

*Medical Mycology 2019; 57: 155 - 160*

### Burgener EB., Sweere JM., Bach MS., Secor PR., Haddock N., Jennings LK., Marvig RL., Johansen HK., Rossi E., Cao X., Tian L., Nedelec L., Molin S., Bollyky PL., Milla CE.

Filamentous bacteriophages are associated with chronic *Pseudomonas* lung infections and antibiotic resistance in cystic fibrosis

*Science Translational Medicine 2019; 11: 488:eaau9748*

### Busatto C., Vianna JS., da Silva LV., Ramis IB., da Silva PEA.

*Mycobacterium avium: an overview*

*Tuberculosis 2019; 114: 127 - 134*

### Cross AR., Goldberg JB.

Remodeling of O Antigen in Mucoid *Pseudomonas aeruginosa* via Transcriptional Repression of *wzz2*

*mBio 2019; 10: 1:e02914-18*

### Degrossi JJ., Merino C., Isasmendi AM., Ibarra LM., Collins C., Bo NE., Papalia M., Fernandez JS., Hernandez CM., Papp-Wallace KM., Bonomo RA., Vazquez MS., Power P., Ramirez MS.

Whole Genome Sequence Analysis of Burkholderia contaminans FFH2055 Strain Reveals the Presence of Putative -Lactamases

*Current Microbiology 2019; 76: 485 - 494*

- Delhaes L., Touati K., Faure-Cognet O., Cornet M., Botterel F., Dannaoui E., Morio F., Le Pape P., Grenouillet F., Favenne L., Le Gal S., Nevez G., Duhamel A., Borman A., Saegeman V., Lagrou K., Gomez E., Carro ML., Canton R., et al**  
 Prevalence, geographic risk factor, and development of a standardized protocol for fungal isolation in cystic fibrosis: Results from the international prospective study "MFIP"  
*Journal of Cystic Fibrosis 2019; 18: 212 - 220*
- Dodemont M., Argudin MA., Willekens J., Vanderhelst E., Pierard D., Deyi VYM., Hanssens L., Franckx H., Schelstraete P., Leroux-Roels I., Nonhoff C., Deplano A., Knoop C., Malfroot A., Denis O.**  
 Emergence of livestock-associated MRSA isolated from cystic fibrosis patients: Result of a Belgian national survey  
*Journal of Cystic Fibrosis 2019; 18: 86 - 93*
- Engel TGP., Slabbers L., de Jong C., Melchers WJG., Hagen F., Verweij PE., Merkus P., Meis JF.**  
 Prevalence and diversity of filamentous fungi in the airways of cystic fibrosis patients - A Dutch, multicentre study  
*Journal of Cystic Fibrosis 2019; 18: 221 - 226*
- Engel TGP., Erren E., Vanden Driessche KSJ., Melchers WJG., Reijers MH., Merkus P., Verweij PE.**  
 Aerosol Transmission of Aspergillus fumigatus in Cystic Fibrosis Patients in the Netherlands  
*Emerging Infectious Diseases 2019; 25: 797 - 799*
- Ersoy MO., Sakarya S., Gunay N., Yilmaz O.**  
 Cystic Fibrosis-Modulated Phenotypic Changes of Pseudomonas aeruginosa May Be a Critical Determinant for Respiratory Infections and Unresponsiveness to Antimicrobial Agents  
*Klinik Journal 2019; 32: 22 - 28*
- Franssens BT., Fluit AC., Rentenaar RJ.**  
 Reproducibility between two readout methods of a commercial broth microdilution assay for Pseudomonas aeruginosa isolates from patients with Cystic Fibrosis  
*Infectious Diseases 2019; 51: 50 - 55*
- Furnari M., De Alessandri A., Cresta F., Haupt M., Bassi M., Calvi A., Haupt R., Bodini G., Ahmed I., Bagnasco F., Giannini EG., Casciaro R.**  
 The role of small intestinal bacterial overgrowth in cystic fibrosis: a randomized case-controlled clinical trial with rifaximin  
*Journal of Gastroenterology 2019; 54: 261 - 270*
- Gallagher T., Phan J., Oliver A., Chase AB., England WE., Wandro S., Hendrickson C., Riedel SF., Whiteson K.**  
 Cystic Fibrosis-Associated Stenotrophomonas maltophilia Strain-Specific Adaptations and Responses to pH  
*Journal of Bacteriology 2019; 201: 7:e00478-18*
- Gardner AI., McClenaghan E., Saint G., McNamara PS., Brodlie M., Thomas MF.**  
 Epidemiology of Nontuberculous Mycobacteria Infection in Children and Young People With Cystic Fibrosis: Analysis of UK Cystic Fibrosis Registry  
*Clinical Infectious Diseases 2019; 68: 731 - 737*
- Gulla KM., Balaji A., Mukherjee A., Jat KR., Sankar J., Lodha R., Kabra SK.**  
 Course of Illness after Viral Infection in Indian Children with Cystic Fibrosis  
*Journal of Tropical Pediatrics 2019; 65: 176 - 182*
- Hedayati MT., Tavakoli M., Maleki M., Heidari S., Mortezaee V., Gheisari M., Hassanzad M., Mirenayat MS., Mandaviani SA., Pourabdollah M., Velayati AA., Vakili M., Abastabar M., Haghani I., Jafarzadeh J., Hedayati N., Seyedmousavi S.**  
 Fungal epidemiology in cystic fibrosis patients with a special focus on *Scedosporium* species complex  
*Microbial Pathogenesis 2019; 129: 168 - 175*
- Hery-Arnaud G., Boutin S., Cuthbertson L., Elborn SJ., Tunney MM.**  
 The lung and gut microbiome: what has to be taken into consideration for cystic fibrosis?  
*Journal of Cystic Fibrosis 2019; 18: 13 - 21*
- Homa M., Sandor A., Toth E., Szebenyi C., Nagy G., Vagvolgyi C., Papp T.**  
 In vitro Interactions of *Pseudomonas aeruginosa* With *Scedosporium* Species Frequently Associated With Cystic Fibrosis  
*Frontiers in Microbiology 2019; 10: ArNo: 441*
- Irvine S., Bunk B., Bayes HK., Sproer C., Connolly JPR., Six A., Evans TJ., Roe AJ., Overmann J., Walker D.**  
 Genomic and transcriptomic characterization of *Pseudomonas aeruginosa* small colony variants derived from a chronic infection model  
*Microbial Genomics 2019; 5: 4:000262*
- Johnson PA.**  
 Novel understandings of host cell mechanisms involved in chronic lung infection: *Pseudomonas aeruginosa* in the cystic fibrotic lung  
*Journal of Infection and Public Health 2019; 12: 242 - 246*
- Jorth P., Ehsan Z., Rezayat A., Caldwell E., Pope C., Brewington JJ., Goss CH., Benscoter D., Clancy JP., Singh PK.**  
 Direct Lung Sampling Indicates That Established Pathogens Dominate Early Infections in Children with Cystic Fibrosis  
*Cell Reports 2019; 27: 1190*
- Kirchhoff L., Olsowski M., Rath PM., Steinmann J.**  
 Exophiala dermatitidis: Key issues of an opportunistic fungal pathogen  
*Virulence 2019; 8: 17:e00107-19*
- Larcher Quinn RA., Adem S., Mills RH., Comstock W., Goldasich LD., Humphrey G., Aksenen AA., Melnik AV., da Silva R., Ackermann G., Bandeira N., Gonzalez DJ., Conrad D., O'Donoghue AJ., Knight R., Dorrestein PC.**  
 Neutrophilic proteolysis in the cystic fibrosis lung correlates with a pathogenic microbiome  
*Microbiome 2019; 7: ArNo: 23*
- Lloyd MG., Vossler JL., Nomura CT., Moffat JF.**  
 Blocking RpoN reduces virulence of *Pseudomonas aeruginosa* isolated from cystic fibrosis patients and increases antibiotic sensitivity in a laboratory strain  
*Scientific Reports 2019; 9: ArNo: 6677*
- R., Lounnas M., Dumont Y., Michon AL., Bonzon L., Chiron R., Carriere C., Klouche K., Godreuil S.**  
 Mycobacterium chimaera Pulmonary Disease in Cystic Fibrosis Patients, France, 2010-2017  
*Emerging Infectious Diseases 2019; 25: 611 - 613*
- Lu MM., Saddi V., Britton PN., Selvadurai H., Robinson PD., Pandit C., Marais B., Fitzgerald DA.**  
 Disease caused by non-tuberculous mycobacteria in children with cystic fibrosis  
*Paediatric Respiratory Reviews 2019; 29: 42 - 52*
- McCurtain JL., Gilbertsen AJ., Evert C., Williams BJ., Hunter RC.**  
 Agmatine accumulation by *Pseudomonas aeruginosa* clinical isolates confers antibiotic tolerance and dampens host inflammation  
*Journal of Medical Microbiology 2019; 68: 446 - 455*
- Millar BC., Nelson D., Moore RE., Rao JR., Moore JE.**  
 Antimicrobial Properties of Basidiomycota Macrofungi to Mycobacterium abscessus Isolated from Patients with Cystic Fibrosis  
*International Journal of Mycobacteriology 2019; 8: 93 - 97*
- Nasri E., Fakhim H., Vaezi A., Khalilzadeh S., Ahangarkani F., Kargar ML., Abtahian Z., Badali H.**  
 Airway colonisation by *Candida* and *Aspergillus* species in Iranian cystic fibrosis patients  
*Mycoses 2019; 62: 434 - 440*
- Oluyombo O., Penfold CN., Diggle SP.**  
 Competition in Biofilms between Cystic Fibrosis Isolates of *Pseudomonas aeruginosa* Is Shaped by R-Pyocins  
*mBio 2019; 10: 1:e01828-18*
- Padrao E., Amorim A.**  
 Subacute invasive aspergillosis in a patient with cystic fibrosis  
*Pulmonology 2019; 25: 126 - 127*

**Pivot D., Fanton A., Badell-Ocando E., Benouachkou M., Astruc K., Huet F., Amoureaux L., Neuwirth C., Criscuolo A., Aho S., Toubiana J., Brisse S.**

Carriage of a Single Strain of Nontoxigenic Corynebacterium diphtheriae bv. Belfanti (Corynebacterium belfanti) in Four Patients with Cystic Fibrosis

*Journal of Clinical Microbiology 2019; 57: 5:UNSP e00042-*

**Ragupathi NKD., Veeraraghavan B.**

Accurate identification and epidemiological characterization of Burkholderia cepacia complex: an update

*Annals of Clinical Microbiology and Antimicrobials 2019; 18: ArNo: 7*

**Ramirez AM., Iribarren ME., Moreno BB., Giron RM.**

Clinical Deterioration Due to Exophiala Dermatitidis in a Patient with Cystic Fibrosis

*Archivos de Bronconeumologia 2019; 55: 162 - 163*

**Ratjen F., Moeller A., McKinney ML., Asherova I., Alon N., Maykut R., Angyalosi G., Bede O., Bolbas K., Bulatov V., Chertok E., Colombo C., Fayon M., Gonczi F., Gouda E., Hammermann J., Munck A., Solomon M., Tsanakas J.**

Eradication of early P-aeruginosa infection in children < 7 years of age with cystic fibrosis: The early study  
*Journal of Cystic Fibrosis 2019; 18: 78 - 85*

**Rees VE., Lucas DSD., Lopez-Causape C., Huang YL., Kotsimbos T., Bulitta JB., Rees MC., Barugahare A., Peleg AY., Nation RL., Oliver A., Boyce JD., Landersdorfer CB.**

Characterization of Hypermутator Pseudomonas aeruginosa Isolates from Patients with Cystic Fibrosis in Australia

*Antimicrobial Agents and Chemotherapy 2019; 63: 4:e02538-18*

**Rojas-Rojas FU., Lopez-Sanchez D., Meza-Radilla G., Mendez-Canarios A., Ibarra JA., Estrada-de los Santos P.**

The controversial Burkholderia cepacia complex, a group of plant growth promoting species and plant, animals and human pathogens  
*Revista Argentina de Microbiologia 2019; 51: 84 - 92*

**Sanchez-Bautista A., Rodriguez-Diaz JC., Garcia-Heredia I., Luna-Paredes C., Alcala-Minagorri PJ.**

Airway microbiota in patients with paediatric cystic fibrosis:

Relationship with clinical status

*Enfermedades Infectuosas y Microbiologia Clinica 2019; 37: 167 - 171*

**Scott JE., Li KW., Filkins LM., Zhu B., Kuchma SL., Schwartzman JD., O'Toole GA.**

Pseudomonas aeruginosa Can Inhibit Growth of Streptococcal Species via Siderophore Production

*Journal of Bacteriology 2019; 201: 8:e00014*

**Singh S., Kaur H., Singh M., Rudramurthy SM., Chakrabarti A.**

Aspergillus terreus Causing Probable Invasive Aspergillosis in a Patient with Cystic Fibrosis  
*Mycopathologia 2019; 184: 151 - 154*

**Sousa AM., Monteiro R., Pereira MO.**

Unveiling the early events of Pseudomonas aeruginosa adaptation in cystic fibrosis airway environment using a long-term in vitro maintenance

*International Journal of Medical Microbiology 2018; 308: 1053 - 1064*

**Stephenson D., Perry A., Appleby MR., Lee D., Davison J., Johnston A., Jones AL., Nelson A., Bourke SJ., Thomas MF., De Soyza A., Lordan JL., Lumb J., Robb AE., Samuel JR., Walton KE., Perry JD.**

An evaluation of methods for the isolation of nontuberculous mycobacteria from patients with cystic fibrosis, bronchiectasis and patients assessed for lung transplantation

*BMC Pulmonary Medicine 2019; 19: ArNo: 19*

**Vasireddy R., Vasireddy S., Brown-Elliott BA., Greninger AL., Davidson RM., Ard KL., Turenne CY., Wallace RJ.**

Mycobacterium talmoniae, a Potential Pulmonary Pathogen Isolated from Multiple Patients with Bronchiectasis in the United States, Including the First Case of Clinical Disease in a Patient with Cystic Fibrosis

*Journal of Clinical Microbiology 2019; 57: 2:UNSP e00906-*

**Warris A.**

Immunopathology of Aspergillus Infections in Children With Chronic Granulomatous Disease and Cystic Fibrosis

*Pediatric Infectious Disease Journal 2019; 38: E96 - E98*

## Nutrition

**Abu-Fraiba Y., Elyashar-Earon H., Shoseyov D., Cohen-Cymberknob M., Armoni S., Kerem E., Wilschanski M.**

Increasing Vitamin D Serum Levels Is Associated With Reduced Pulmonary Exacerbations in Patients With Cystic Fibrosis

*Journal of Pediatric Gastroenterology and Nutrition 2019; 68: 110 - 115*

**Bernhard W., Lange R., Graepel-Mainka U., Engel C., Machann J., Hund V., Shunova A., Hector A., Riethmuller J.**

Choline Supplementation in Cystic Fibrosis-The Metabolic and Clinical Impact

*Nutrients 2019; 11: 3:656*

**Calvo-Lerma J., Fornes-Ferrer V., Peinado I., Heredia A., Ribes-Koninekx C., Andres A.**

A first approach for an evidence-based in vitro digestion method to adjust pancreatic enzyme replacement therapy in cystic fibrosis

*PLoS One 2019; 14: 2:e0212459*

**Calvo-Lerma J., Hulst J., Boon M., Colombo C., Masip E., Ruperto M., Fornes-Ferrer V., van der Wiel E., Claes I., Garriga M., Roca M., Crespo-Escobar P., Bulfamante A., Woodcock S., Martinez-Barona S., Andres A., de Boeck K., Ribes-K**

Clinical validation of an evidence-based method to adjust Pancreatic Enzyme Replacement Therapy through a prospective interventional study in paediatric patients with Cystic Fibrosis  
*PLoS One 2019; 14: 3:e0213216*

**Declerq D., Van Meerhaeghe S., Marchand S., Van Braeckel E., van Daele S., De Baets F., Van Biervliet S.**

The nutritional status in CF: Being certain about the uncertainties  
*Clinical Nutrition Espen 2019; 29: 15 - 21*

**Le TN.**

Updates in vitamin D therapy in cystic fibrosis

*Current Opinion in Endocrinology Diabetes and Obesity 2018; 25: 361 - 365*

**Monge MFE., Barrado E., Vicente CA., del Rio MPR., de Miguel Sanz JMM.**

Zinc Nutritional Status in Patients with Cystic Fibrosis

*Nutrients 2019; 11: 1:150*

**Neri LDL., Taminato M., da Silva LVRF.**

Systematic Review of Probiotics for Cystic Fibrosis Patients: Moving Forward

*Journal of Pediatric Gastroenterology and Nutrition 2019; 68: 394 - 399*

**Sainath NN., Schall J., Bertolaso C., McAnlis C., Stallings VA.**

Italian and North American dietary intake after ivacaftor treatment for Cystic Fibrosis Gating Mutations

*Journal of Cystic Fibrosis 2019; 18: 135 - 143*

**Tangpricha V., Lukemire J., Chen YQ., Binongo JNG., Judd SE., Michalski ES., Lee MJ., Walker S., Ziegler TR., Tirouvanziam R., Zughaier SM., Chedsachai S., Hermes WA., Chmiel JF., Grossmann RE., Gaggar A., Joseph PM., Alvarez JA.**

Vitamin D for the Immune System in Cystic Fibrosis (DISC): a double-blind, multicenter, randomized, placebo-controlled clinical trial

*American Journal of Clinical Nutrition 2019; 109: 544 - 553*

**Timmers NKLM., Stellato RK., van der Ent CK., Houwen RHJ., Woestenenk JW.**

Vitamin D intake, serum 25-hydroxy vitamin D and pulmonary function in paediatric patients with cystic fibrosis: a longitudinal approach

*British Journal of Nutrition 2019; 121: 195 - 201*

**Wani WA., Nazir M., Bhat JI., Malik EU., Ahmad QI., Charoo BA., Ali SW.**

Vitamin D status correlates with the markers of cystic fibrosis-related pulmonary disease

*Pediatrics and Neonatology 2019; 60: 210 - 215*

## Physiotherapy

**Lang RL., Wilson C., Stockton K., Russell T., Johnston LM.**  
CyFiT telehealth: protocol for a randomised controlled trial of an online outpatient physiotherapy service for children with cystic fibrosis  
*BMC Pulmonary Medicine 2019; 19: ArNo: 21*

**O'Sullivan KJ., Collins L., McGrath D., Linnane B., O'Sullivan L., Dunne CP.**  
Oscillating Positive Expiratory Pressure Therapy May Be Performed Poorly by Children With Cystic Fibrosis  
*Respiratory Care 2019; 64: 398 - 405*

**Wilson LM., Morrison L., Robinson KA.**  
Airway clearance techniques for cystic fibrosis: an overview of Cochrane systematic reviews  
*Cochrane Database of Systematic Reviews 2019; : 1:CD011231*

**Zeren M., Cakir E., Gurses HN.**  
Effects of inspiratory muscle training on postural stability, pulmonary function and functional capacity in children with cystic fibrosis: A randomised controlled trial  
*Respiratory Medicine 2019; 148: 24 - 30*

## Psychosocial

**Abbott J., Havermans T., Jaryvholt S., Landau E., Prins Y., Smrekar U., Staab D., Verity L., Verkleij M.**  
Mental Health screening in cystic fibrosis centres across Europe  
*Journal of Cystic Fibrosis 2019; 18: 299 - 303*

**Arden MA., Drabble S., O'Cathain A., Hutchings M., Wildman M.**  
Adherence to medication in adults with Cystic Fibrosis: An investigation using objective adherence data and the Theoretical Domains Framework  
*British Journal of Health Psychology 2019; 24: 357 - 380*

**Cronly J., Duff A., Riekert K., Horgan A., Lehane E., Perry I., Fitzgerald A., Howe B., Chroinin MN., Savage E.**  
Positive mental health and wellbeing in adults with cystic fibrosis: A cross sectional study  
*Journal of Psychosomatic Research 2019; 116: 125 - 130*

**Cronly JA., Duff AJ., Riekert KA., Fitzgerald AP., Perry IJ., Lehane EA., Horgan A., Howe BA., Chroinin MN., Savage E.**  
Health-Related Quality of Life in Adolescents and Adults With Cystic Fibrosis: Physical and Mental Health Predictors  
*Respiratory Care 2019; 64: 406 - 415*

**Cronly J., Horgan AM., Lehane E., Howe B., Duff AJ., Riekert KA., Perry IJ., Fitzgerald AP., Chroinin MN., Savage E.**  
Anxiety and Depression in Parent Caregivers of Children with Cystic Fibrosis  
*Journal of Child and Family Studies 2019; 28: 1304 - 1312*

**Cronly J., Savage E.**  
Positive mental health and wellbeing in adolescents with cystic fibrosis  
*Journal of Psychosomatic Research 2019; 116: 131 - 132*

**Foil KE., Powers A., Raraigh KS., Wallis K., Southern KW., Salinas D.**  
The increasing challenge of genetic counseling for cystic fibrosis  
*Journal of Cystic Fibrosis 2019; 18: 167 - 174*

**Hind D., Drabble SJ., Arden MA., Mandefield L., Waterhouse S., Maguire C., Cantrill H., Robinson L., Beever D., Scott AJ., Keating S., Hutchings M., Bradley J., Nightingale J., Allenby MI., Dewar J., Whelan P., Ainsworth J., et al**  
Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study  
*BMC Pulmonary Medicine 2019; 19: ArNo: 77*

**Hoo ZH., Wildman MJ., Campbell MJ., Walters SJ., Gardner B.**  
A pragmatic behavior-based habit index for adherence to nebulized treatments among adults with cystic fibrosis  
*Patient Preference and Adherence 2019; 13: 283 - 294*

**Hosseinzadeh SS., Rafeey M., Vahedi L., Noorazar SG.**

The Frequency of Psychiatric Disorders in Cystic Fibrosis Patients Aged 5-18 Years in Northwest of Iran  
*Crescent Journal of Medical and Biological Sciences 2019; 6: 56 - 60*

**Maras D., Balfour L., Tasca GA., Gaudet E., Aaron SD., Cameron WD., Pakhale S.**  
Breathlessness catastrophizing relates to poorer quality of life in adults with cystic fibrosis  
*Journal of Cystic Fibrosis 2019; 18: 150 - 157*

**Oates GR., Stepanikova I., Rowe SM., Gamble S., Gutierrez HH., Harris WT.**  
Objective Versus Self-Reported Adherence to Airway Clearance Therapy in Cystic Fibrosis  
*Respiratory Care 2019; 64: 176 - 181*

**Saxby N., Beggs S., Battersby M., Lawn S.**  
What are the components of effective chronic condition self-management education interventions for children with asthma, cystic fibrosis, and diabetes? A systematic review  
*Patient Education and Counseling 2019; 102: 607 - 622*

**Tomaszek L., Debska G., Cepuch G., Kulpa M., Pawlik L., Broniatowska E.**  
Evaluation of quality of life predictors in adolescents and young adults with cystic fibrosis  
*Heart & Lung 2019; 48: 159 - 165*

**Wilson C., Duckers J., Speight L., Lau D., Ketchell RI., Edwards A.**  
Assessment of Sexual Reproductive Health Knowledge Amongst Patients with Cystic Fibrosis  
*Sexuality and Disability 2019; 37: 15 - 23*

## Pulmonology

**Bell SC., Stuart RL.**

Infection risks for patients from healthcare workers with cystic fibrosis  
*Respirology 2019; 24: 393 - 394*

**Bernaldez CB., Pacheco VA., Morales ASV., Martin PJR.**  
Adult Cystic Fibrosis: A Possible Cause of Bronchiectasis in COPD Patients  
*Archivos de Bronconeumologia 2019; 55: 163 - 164*

**Castner LM., Nasr SZ., Arteta M.**

Progressive Scoliosis in a Child with Cystic Fibrosis  
*Case Reports in Pediatrics 2019; : ArNo: 1471879*

**Esther CR., Muhlebach MS., Ehre C., Hill DB., Wolfgang MC., Kesimer M., Ramsey KA., Markovetz MR., Garbarine IC., Forest MG., Seim I., Zorn B., Morrison CB., Delion MF., Thelin WR., Villalon D., Sabater JR., Turkovic L., et al**  
Mucus accumulation in the lungs precedes structural changes and infection in children with cystic fibrosis  
*Science Translational Medicine 2019; 11: 486:eaav3488*

**Fernandez-Petty CM., Hughes GW., Bowers HL., Watson JD., Rosen BH., Townsend SM., Santos C., Ridley CE., Chu KK., Birket SE., Li Y., Leung HM., Mazur M., Garcia BA., Evans TIA., Libby EF., Hathorne H., Hanes J., Tearney GJ., et al**  
A glycopolymers improves vasoelasticity and mucociliary transport of abnormal cystic fibrosis mucus  
*JCI Insight 2019; 7: 4:e13362*

**Gold LS., Patrick DL., Hansen RN., Beckett V., Goss CH., Kessler L.**

Correspondence between symptoms and preference-based health status measures in the STOP study  
*Journal of Cystic Fibrosis 2019; 18: 251 - 264*

**Halderman AA., Lee S., London NR., Day A., Jain R., Moore JA., Lin SY.**  
Impact of high- versus low-risk genotype on sinonasal radiographic disease in cystic fibrosis  
*Laryngoscope 2019; 129: 788 - 793*

- Hernandez R., Delpiano L., Amador J., Arias M., Delgado JC.**  
Neutropenia associated with the use of cefepime in pediatric patients with cystic fibrosis  
*Revista Chilena de Infectologia* 2019; 36: 112 - 114
- Khalaf RT., Green D., Amankwah EK., Peck J., Carr V., Goldenberg NA., Wilsey M.**  
Percutaneous Endoscopic Gastrostomy Tubes May Be Associated With Preservation of Lung Function in Patients With Cystic Fibrosis  
*Nutrition in Clinical Practice* 2019; 34: 290 - 296
- Khan MA., Ali ZS., Sweezy N., Grasemann H., Palaniyar N.**  
Progression of Cystic Fibrosis Lung Disease from Childhood to Adulthood: Neutrophils, Neutrophil Extracellular Trap (NET) Formation, and NET Degradation  
*Genes* 2019; 10: 3:183
- Korten I., Kieninger E., Yammie S., Cangiano G., Nyilas S., Anagnostopoulou P., Singer F., Kuehni CE., Regamey N., Frey U., Casaulta C., Spycher BD., Latzin P., Barben J., Casaulta C., Jung A., Kieninger E., Korten I., Latzin P.,**  
Respiratory rate in infants with cystic fibrosis throughout the first year of life and association with lung clearance index measured shortly after birth  
*Journal of Cystic Fibrosis* 2019; 18: 118 - 126
- Lombardi E., Gambazza S., Pradal U., Braggion C.**  
Lung clearance index in subjects with cystic fibrosis in Italy  
*Italian Journal of Pediatrics* 2019; 45: ArNo: 56
- Matusovsky OS., Kachmar L., Ijpmma G., Panariti A., Benedetti A., Martin JG., Lauzon AM.**  
Contractile Properties of Intrapulmonary Airway Smooth Muscle in Cystic Fibrosis  
*American Journal of Respiratory Cell and Molecular Biology* 2019; 60: 434 - 444
- McCormack P., Burnham P., Southern KW.**  
A systematic Cochrane Review of autogenous drainage (AD) for airway clearance in cystic fibrosis  
*Paediatric Respiratory Reviews* 2019; 29: 23 - 24
- McElvane OJ., Gunaratnam C., Reeves EP., McElvane NG.**  
A specialized method of sputum collection and processing for therapeutic interventions in cystic fibrosis  
*Journal of Cystic Fibrosis* 2019; 18: 203 - 211
- Melnik V., Phillips D., Schisler T., Subramaniam K.**  
Cystic Fibrosis and Lower-Extremity Edema: A Case of Intraoperative Diagnosis of Acute Deep Venous Thrombosis and Pulmonary Embolism in a Double-Lung Transplant Recipient Using Point-of-Care Ultrasound  
*Journal of Cardiothoracic and Vascular Anesthesia* 2019; 33: 506 - 510
- Mirza AA., Robinson TE., Gifford K., Guo HH.**  
3D Printing and the Cystic Fibrosis Lung  
*Journal of Cystic Fibrosis* 2019; 18: 278 - 279
- Parazzi PLF., Marson FAL., Ribeiro MAGO., Schivinski CIS., Ribeiro JD.**  
Correlation between parameters of volumetric capnography and spirometry during a submaximal exercise protocol on a treadmill in patients with cystic fibrosis and healthy controls  
*Pulmonology* 2019; 25: 21 - 31
- Pecellin ID., Ortega MM., Hernandez LC., Barrera LM., Zara PM., Valera MJM., Gallego MEQ.**  
Persistent Atelectasis in a Patient With Cystic Fibrosis: Are Antibiotics Always Needed?  
*Archivos de Bronconeumologia* 2019; 55: 54 - 55
- Pletcher SD., Goldberg AN., Cope EK.**  
Loss of Microbial Niche Specificity Between the Upper and Lower Airways in Patients With Cystic Fibrosis  
*Laryngoscope* 2019; 129: 544 - 550
- Poncin W., Lebecque P.**  
Lung clearance index in cystic fibrosis  
*Revue des Maladies Respiratoires* 2019; 36: 377 - 395
- Rafeey M., Moghaddam YJ., Rezaeeyan S.**  
Sinonasal Manifestations in Children with Cystic Fibrosis  
*Iranian Journal of Pediatrics* 2019; 29: 1:e66015
- Rossi GA., Morelli P., Galletta LJ., Colin AA.**  
Airway microenvironment alterations and pathogen growth in cystic fibrosis  
*Pediatric Pulmonology* 2019; 54: 497 - 506
- Schultz A., Marsh JA., Saville BR., Norman R., Middleton PG., Greville HW., Bellgard MI., Berry SM., Snelling T.**  
Trial Refresh: A Case for an Adaptive Platform Trial for Pulmonary Exacerbations of Cystic Fibrosis  
*Frontiers in Pharmacology* 2019; 10: ArNo: 301
- Thomas M., Bagg W., Kolbe J.**  
Infection risks for patients from healthcare workers with cystic fibrosis  
*Respirology* 2019; 24: 392 - 393
- ## Radiology
- Corcoran TE., Huber AS., Myerburg MM., Weiner DJ., Locke LW., Lacy RT., Weber L., Czachowski MR., Johnston DJ., Muthukrishnan A., Lennox AT., Pilewski JM.**  
Multiprobe Nuclear Imaging of the Cystic Fibrosis Lung as a Biomarker of Therapeutic Effect  
*Journal of Aerosol Medicine and Pulmonary Drug Delivery* 2019; 27: 794 - 802
- Crisafulli E., Teopompi E., Luceri S., Longo F., Tzani P., Pagano P., Ielpo A., Longo C., Di Paolo M., Sverzellati N., Palange P., Chetta A., Pisi G.**  
The value of high-resolution computed tomography (HRCT) to determine exercise ventilatory inefficiency and dynamic hyperinflation in adult patients with cystic fibrosis  
*Respiratory Research* 2019; 20: ArNo: 78
- Robinson P., Morgan L.**  
Bronchiectasis in PCD looks different to CF on CT scan  
*Multidisciplinary Respiratory Medicine* 2018; 13:
- Santyr G., Kanhere N., Morgado F., Rayment JH., Ratjen F., Couch MJ.**  
Hyperpolarized Gas Magnetic Resonance Imaging of Pediatric Cystic Fibrosis Lung Disease  
*Academic Radiology* 2019; 26: 344 - 354
- Sasihuseyinoglu AS., Altintas DU., Soyupak S., Dogruel D., Yilmaz M., Serbes M., Duyuler G.**  
Evaluation of high resolution computed tomography findings of cystic fibrosis  
*Korean Journal of Internal Medicine* 2019; 34: 335 - 343
- Schutz K., Alecsandru D., Grimbacher B., Haddock J., Bruining A., Driessens G., de Vries E., van Hagen PM., Hartmann I., Fraioli F., Milito C., Mitrevski M., Quinti I., Serra G., Kelleher P., Loebinger M., Litzman J., Postranecka V.**  
Imaging of Bronchial Pathology in Antibody Deficiency: Data from the European Chest CT Group  
*Journal of Clinical Immunology* 2019; 39: 45 - 54
- Sodhi KS., Gupta P., Shrivastav A., Saxena AK., Mathew JL., Singh M., Agarwal R.**  
Evaluation of 3 T lung magnetic resonance imaging in children with allergic bronchopulmonary aspergillosis: Pilot study  
*European Journal of Radiology* 2019; 111: 88 - 92
- Tadd K., Morgan L., Rosenow T., Schultz A., Susanto C., Murray C., Robinson P.**  
CF derived scoring systems do not fully describe the range of structural changes seen on CT scans in PCD  
*Pediatric Pulmonology* 2019; 54: 471 - 477
- ## Screening
- Dankert-Roelse JE., Bouva MJ., Jakobs BS., Janssens HM., de Winter-de Groot KM., Schonbeck Y., Gille JJP., Gulmans VAM., Verschoof-Puite RK., Schielen PCJI., Verkerk PH.**  
Newborn blood spot screening for cystic fibrosis with a four-step screening strategy in the Netherlands  
*Journal of Cystic Fibrosis* 2019; 18: 54 - 63

- Davies G., Aurora P.**  
A Simple Screening Test for Cystic Fibrosis?  
*Indian Pediatrics* 2019; 56: 105 - 106
- DiBattista A., McIntosh N., Lamoureux M., Al-Dirbashi OY., Chakraborty P., Britz-McKibbin P.**  
Metabolic Signatures of Cystic Fibrosis Identified in Dried Blood Spots For Newborn Screening Without Carrier Identification  
*Journal of Proteome Research* 2019; 18: 841 - 854
- Gartner S., Mondejar-Lopez P., de la Cruz OA., Alonso MJ., Alvarez M., Martin AA., de Aguero MIBG., Perez MJC., Aguilera PC., Roig MC., Aznar-Perez IC., Colomer JC., Pecellin ID., Montaner AE., Mulet JF., Hernandez GG., Guayarte P.**  
Follow-up protocol of patients with cystic fibrosis diagnosed by newborn screening  
*Anales de Pediatría* 2019; 90: 4:UNSP 251.e1
- Holtkamp KCA., Henneman L., Gille JJP., Meijers-Heijboer H., Cornel MC., Lakeman P.**  
Direct-to-consumer carrier screening for cystic fibrosis via a hospital website: a 6-year evaluation  
*Journal of Community Genetics* 2019; 10: 249 - 257
- Ortega L., Llorella A., Esquivel JP., Sabate N.**  
Self-powered smart patch for sweat conductivity monitoring  
*Microsystems & Nanoengineering* 2019; 5: ArNo: UNSP 3
- Singh A., Lodha R., Shastri S., Sethuraman G., Sreedevi KN., Kabra M., Kabra SK.**  
Aquagenic Wrinkling of Skin: A Screening Test for Cystic Fibrosis  
*Indian Pediatrics* 2019; 56: 109 - 113
- ## Therapy (Non Antimicrobial)
- Barquiero N.**  
Eluforsen CFTR (mutant) expression inhibitor Treatment of cystic fibrosis  
*Drugs of the Future* 2019; 44: 5 - 9
- Berical A., Lee RE., Randell SH., Hawkins F.**  
Challenges Facing Airway Epithelial Cell-Based Therapy for Cystic Fibrosis  
*Frontiers in Pharmacology* 2019; 10: ArNo: 74
- Berkers G., van Mourik P., Vonk AM., Kruisselbrink E., Dekkers JF., de Winter-de Groot KM., Arets HGM., Marck-van der Wilt REP., Dijkema JS., Vanderschuren MM., Houwen RHJ., Heijerman HGM., van de Graaf EA., Elias SG., Majoor CJ., et al**  
Rectal Organoids Enable Personalized Treatment of Cystic Fibrosis  
*Cell Reports* 2019; 26: 1701 - +
- Bitonti M., Fritts L., So TY.**  
A Review on the Use of Cystic Fibrosis Transmembrane Conductance Regulator Gene Modulators in Pediatric Patients  
*Journal of Pediatric Health Care* 2019; 33: 356 - 364
- Bodas M., Vij N.**  
Adapting Proteostasis and Autophagy for Controlling the Pathogenesis of Cystic Fibrosis Lung Disease  
*Frontiers in Pharmacology* 2019; 10: ArNo: 20
- Cabrini G.**  
Innovative Therapies for Cystic Fibrosis: The Road from Treatment to Cure  
*Molecular Diagnosis & Therapy* 2019; 23: 263 - 279
- Cheng PC., Alexiou S., Rubenstein RC.**  
Safety and efficacy of treatment with lumacaftor in combination with ivacaftor in younger patients with cystic fibrosis  
*Expert Review of Respiratory Medicine* 2019; 13: 417 - 423
- Cho DY., Lim DJ., Mackey C., Skinner D., Zhang SY., McCormick J., Woodworth BA.**  
Ivacaftor, a Cystic Fibrosis Transmembrane Conductance Regulator Potentiator, Enhances Ciprofloxacin Activity Against *Pseudomonas aeruginosa*  
*American Journal of Rhinology & Allergy* 2019; 33: 129 - 136
- Clancy JP., Cotton CU., Donaldson SH., Solomon GM., VanDevanter DR., Boyle MP., Gentzsch M., Nick JA., Illek B., Wallenburg JC., Sorscher EJ., Amaral MD., Beekman JM., Naren AP., Bridges RJ., Thomas PJ., Cutting G., Rowe S., et al**  
CFTR modulator therotyping: Current status, gaps and future directions  
*Journal of Cystic Fibrosis* 2019; 18: 22 - 34
- Clarke LA., Awatade NT., Felicio VM., Silva IA., Calucho M., Pereira L., Azevedo P., Cavaco J., Barreto C., Bertuzzo C., Gartner S., Beekman J., Amaral MD.**  
The effect of premature termination codon mutations on CFTR mRNA abundance in human nasal epithelium and intestinal organoids: a basis for read-through therapies in cystic fibrosis  
*Human Mutation* 2019; 40: 326 - 334
- Collins MS., O'Brien M., Schramm CM., Murray TS.**  
Repeated hot water and steam disinfection of Pari LC Plus (R) nebulizers alter nebulizer output  
*Journal of Cystic Fibrosis* 2019; 18: 233 - 235
- Cristallini C., Barbani N., Ventrelli L., Summa C., Filippi S., Capeloa T., Vitale E., Albera C., Messore B., Giachino C.**  
Biodegradable microparticles designed to efficiently reach and act on cystic fibrosis mucus barrier  
*Materials Science & Engineering C-Materials for Biological* 2019; 95: 19 - 28
- De la Hoz D., Osorio MV., Restrepo-Gualteros SM.**  
Cystic fibrosis transmembrane conductance regulator modulators: Present and future in cystic fibrosis treatment. A review  
*Archivos Argentinos de Pediatría* 2019; 117: E131 - E135
- Ehre C., Rushton ZL., Wang BY., Hothem LN., Morrison CB., Fontana NC., Markovetz MR., Delion MF., Kato T., Villalon D., Thelin WR., Esther CR., Hill DB., Grubb BR., Livraghi-Butrico A., Donaldson SH., Boucher RC.**  
An Improved Inhaled Mucolytic to Treat Airway Muco-obstructive Diseases  
*American Journal of Respiratory and Critical Care Medicine* 2019; 199: 171 - 180
- Eickmeier O., Smaczyñ C., Rohde G., Schmitt-Grohé S.**  
Cystic fibrosis-from newborn screening to occupational guidance  
*Pneumologie* 2019; 16: 19 - 26
- Garbuzenko OB., Khah N., Kuzmov A., Pogrebnyak N., Pozharov V., Minko T.**  
Inhalation treatment of cystic fibrosis with lumacaftor and ivacaftor co-delivered by nanostructured lipid carriers  
*Journal of Controlled Release* 2019; 296: 225 - 231
- Gomez-Pastrana D., Nwokoro C., McLean M., Brown S., Christiansen N., Pao CS.**  
Real-world effectiveness of ivacaftor in children with cystic fibrosis and the G551D mutation  
*Analyses de Pediatría* 2019; 90: 148 - 156
- Griesser J., Hetenyi G., Federer C., Steinbring C., Ellemunter H., Niedermayr K., Bernkop-Schnurch A.**  
Highly mucus permeating and zeta potential changing self-emulsifying drug delivery systems: A potent gene delivery model for causal treatment of cystic fibrosis  
*International Journal of Pharmaceutics* 2019; 557: 124 - 134
- Guimbellot J., Solomon GM., Baines A., Heltshe SL., VanDalfsen J., Joseloff E., Sagel SD., Rowe SM.**  
Effectiveness of ivacaftor in cystic fibrosis patients with non-G551D gating mutations  
*Journal of Cystic Fibrosis* 2019; 18: 102 - 109
- Hayes D., Kopp BT., Hill CL., Lallier SW., Schwartz CM., Tadesse M., Alsudayri A., Reynolds SD.**  
Cell Therapy for Cystic Fibrosis Lung Disease: Regenerative Basal Cell Amplification  
*Stem Cells Translational Medicine* 2019; 8: 225 - 235
- Ideou JE., Zhang X., McColley S., Levy H.**  
Transcriptome Profiling and Molecular Therapeutic Advances in Cystic Fibrosis: Recent Insights  
*Genes* 2019; 10: 3:180

- Jeong JH., Lee N., Tucker MA., Rodriguez-Miguel P., Looney J., Thomas J., Derella CC., El-Marakby A., Musall JB., Sullivan JC., McKie KT., Forseen C., Davison GW., Harris RA.**  
Tetrahydrobiopterin improves endothelial function in patients with cystic fibrosis  
*Journal of Applied Physiology* 2019; 126: 60 - 66
- Kelly A., De Leon DD., Sheikh S., Camburn D., Kubrak C., Peleckis AJ., Stefanovski D., Hadjiliadis D., Rickels MR., Rubenstein RC.**  
Islet Hormone and Incretin Secretion in Cystic Fibrosis after Four Months of Ivacaftor Therapy  
*American Journal of Respiratory and Critical Care Medicine* 2019; 199: 342 - 351
- Kirwan L., Fletcher G., Harrington M., Jeleniewska P., Zhou SJ., Casserly B., Gallagher CG., Greally P., Gunaratnam C., Herzog M., Linnane B., McElvaney NG., McKone EF., McNally P., Mullane D., Chronin MN., O'Mahony M., Plant BJ., et al**  
Longitudinal Trends in Real-World Outcomes after Initiation of Ivacaftor A Cohort Study from the Cystic Fibrosis Registry of Ireland  
*Annals of the American Thoracic Society* 2019; 16: 209 - 216
- Li A., Vigers T., Pyle L., Zemanick E., Nadeau K., Sagel SD., Chan CL.**  
Continuous glucose monitoring in youth with cystic fibrosis treated with lumacaftor-ivacaftor  
*Journal of Cystic Fibrosis* 2019; 18: 144 - 149
- Luan XJ., Tam JS., Belev G., Jagadeeshan S., Murray B., Hassan N., Machen TE., Chapman LD., Janowski JP.**  
Nebulized hypertonic saline triggers nervous system-mediated active liquid secretion in cystic fibrosis swine trachea  
*Scientific Reports* 2019; 9: ArNo: 540
- McColley SA., Konstan MW., Ramsey BW., Elborn JS., Boyle MP., Wainwright CE., Waltz D., Vera-Llonch M., Marigowda G., Jiang JG., Rubin JL.**  
Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV1  
*Journal of Cystic Fibrosis* 2019; 18: 94 - 101
- McCormick J., Cho DY., Lampkin B., Richman J., Hathorne H., Rowe SM., Woodworth BA.**  
Ivacaftor improves rhinologic, psychologic, and sleep-related quality of life in G551D cystic fibrosis patients  
*International Forum of Allergy & Rhinology* 2019; 9: 292 - 297
- McNamara J., McColley SA., Marigowda G., Liu F., Tian S., Owen CA., Stiles D., Li CH., Waltz D., Wang LDT., Sawicki GS.**  
Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study  
*Lancet Respiratory Medicine* 2019; 7: 325 - 335
- Nagy B., Bene Z., Fejes Z., Heitsche SL., Reid D., Ronan NJ., McCarthy Y., Smith D., Nagy A., Joscelynn E., Balla G., Kappelmayr J., Macek M., Bell SC., Plant BJ., Amaral MD., Balogh I.**  
Human epididymis protein 4 (HE4) levels inversely correlate with lung function improvement (delta FEV1) in cystic fibrosis patients receiving ivacaftor treatment  
*Journal of Cystic Fibrosis* 2019; 18: 271 - 277
- Newsome SJ., Daniel RM., Carr SB., Bilton D., Keogh RH.**  
Investigating the effects of long-term dornase alfa use on lung function using registry data  
*Journal of Cystic Fibrosis* 2019; 18: 110 - 117
- Ong V., Mei V., Cao L., Lee K., Chung EJ.**  
Nanomedicine for Cystic Fibrosis  
*Slas Technology* 2019; 24: 169 - 180
- Pranke I., Golec A., Hinzpeter A., Edelman A., Sermet-Gaudelus I.**  
Emerging Therapeutic Approaches for Cystic Fibrosis. From Gene Editing to Personalized Medicine  
*Frontiers in Pharmacology* 2019; 10: ArNo: 121
- Rey MM., Bonk MP., Hadjiliadis D.**  
Cystic Fibrosis: Emerging Understanding and Therapies  
*Annual Review of Medicine*, Vol 70 2019; 70: 197 - 210
- Sadowska B., Wojcik U., Krzyzanowska-Kowalczyk J., Kowalczyk M., Stochmal A., Rywaniak J., Burzynska J., Rozalska B.**  
The Pros and Cons of Cystic Fibrosis (CF) Patient Use of Herbal Supplements Containing Pulmonaria officinalis L. Extract: the Evidence from an In Vitro Study on *Staphylococcus aureus* CF Clinical Isolates  
*Molecules* 2019; 24: 6:1151
- Sesma JI., Wu B., Stuhlmiller TJ., Scott DW.**  
SPX-101 is stable in and retains function after exposure to cystic fibrosis sputum  
*Journal of Cystic Fibrosis* 2019; 18: 244 - 250
- Skilton M., Krishan A., Patel S., Sinha IP., Southern KW.**  
Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis  
*Cochrane Database of Systematic Reviews* 2019; : 1:CD009841
- van de Peppel IP., Doktorova M., Berkers G., de Jonge HR., Houwen RHJ., Verkade HJ., Jonker JW., Bodebes FAJA.**  
IVACAFTOR restores FGF19 regulated bile acid homeostasis in cystic fibrosis patients with an S1251N or a G551D gating mutation  
*Journal of Cystic Fibrosis* 2019; 18: 286 - 293
- van Koningsbruggen-Rietschel S.**  
Novel treatment modalities for cystic fibrosis  
*Pneumologie* 2019; 16: 88 - 97
- Warren E., Morgan K., Toward TJ., Schwenkglenks M., Leadbetter J.**  
Cost Effectiveness of Inhaled Mannitol (Bronchitol((R))) in Patients with Cystic Fibrosis  
*Pharmacoeconomics* 2019; 37: 435 - 446
- Wu HX., Zhu M., Xiong XF., Wei J., Zhuo KQ., Cheng DY.**  
Efficacy and Safety of CFTR Corrector and Potentiator Combination Therapy in Patients with Cystic Fibrosis for the F508del-CFTR Homozygous Mutation: A Systematic Review and Meta-analysis  
*Advances in Therapy* 2019; 36: 451 - 461
- ## Transplantation
- Klee P., Dirlewanger M., Lavallard V., McLin VA., Mornand A., Pernin N., Petit LM., Soccal PM., Wildhaber BE., Zumsteg U., Blouin JL., Berney T., Schwitzgebel VM.**  
Combined Pancreatic Islet-Lung-Liver Transplantation in a Pediatric Patient with Cystic Fibrosis-Related Diabetes  
*Hormone Research in Pediatrics* 2018; 90: 270 - 274
- Los-Arcos I., Len O., Martin-Gomez MT., Gonzalez-Lopez JJ., Saez-Gimenez B., Deu M., Nuvials X., Ferrer R., Roman A., Gavalda J.**  
Lung transplantation in two cystic fibrosis patients infected with previously pandrug-resistant Burkholderia cepacia complex treated with ceftazidime-avibactam  
*Infection* 2019; 47: 289 - 292
- Luparello P., Lazio MS., Voltolini L., Borchi B., Taccetti G., Maggiore G.**  
Outcomes of endoscopic sinus surgery in adult lung transplant patients with cystic fibrosis  
*European Archives of Oto-Rhino-Laryngology* 2019; 276: 1341 - 1347
- Mendogni P., Henchi S., Morlacchi LC., Tosi D., Nosotti M., Tarsia P., Gregorini AI., Rosso L.**  
Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorders in Cystic Fibrosis Lung Transplant Recipients: A Case Series  
*Transplantation Proceedings* 2019; 51: 194 - 197
- Novel-Catin E., Pelletier S., Reynaud Q., Nove-Josserand R., Durupt S., Dubourg L., Durieu I., Fouque D.**  
Aminoglycoside exposure and renal function before lung transplantation in adult cystic fibrosis patients  
*Nephrology Dialysis Transplantation* 2019; 34: 118 - 122

**Ochman M., Latoś M., Urlik M., Stacel T., Necki M., Tatoj Z.,  
Zawadzki F., Wajda-Pokrontka M., Przybyłowski P., Zembala M.**  
Cystic Fibrosis: From Qualification to Lung Transplantation, a Single  
Center Experience  
*Annals of Transplantation* 2019; 24: 185 - 190

**Raats D., Lorent N., Saegeman V., Vos R., van Ingen J., Verleden  
G., Van Raemdonck D., Dupont L.**

Successful lung transplantation for chronic Mycobacterium abscessus  
infection in advanced cystic fibrosis, a case series  
*Transplant Infectious Disease* 2019; 21: e13046

**Welsner M., Straburg S., Taube C., Sutharsan S.**  
Use of ivacaftor in late diagnosed cystic fibrosis monozygotic twins  
heterozygous for F508del and R117H-7T-a case report  
*BMC Pulmonary Medicine* 2019; 19: ArNo: 76